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ABSTRACT 
Clozapine is an antipsychotic drug (APD) with a uniquely efficacious therapeutic profile 
that is preeminent for treatment resistant schizophrenia.  A common property of all 
clinically available APDs is that they bind D2-like dopamine receptors at therapeutic 
concentrations.  However, unique molecular actions for clozapine that are different from 
all other APDs have not been established.  Here we show that treatment with all APDs 
upregulates cell-surface expression of D2-dopamine receptors (D2R), relative to that 
produced by clozapine.  Multiple experiments, including a pulse-chase assay for surface 
D2R indicated that the APD-mediated upregulation of D2R is due to enhanced insertion of 
D2R into the plasma membrane and not differences in receptor occupancy or protein 
synthesis.  The potency of amisulpride, an APD with poor membrane permeability, for 
upregulating surface D2R was increased by coexpressing OCT1, an amisulpride 
transporter, suggesting an intracellular site of action for APDs.  Competition experiments 
and experiments with a non-APD-binding D2R mutant indicated that APD upregulation of 
surface D2R is a consequence of direct receptor binding.  Enhancement by APDs of 
surface D2R, relative to that produced by clozapine, was magnified in both a 
glycosylation-deficient and a misfolding D2R mutant.  Moreover, every APD, except 
clozapine, enhanced the detergent solubility of intracellular D2R.  These and other data 
suggest that APDs act intracellularly as chemical chaperones to stabilize a conformation 
of D2R with enhanced detergent solubility and transport to the cell surface.  These results 
display a unique molecular event of clozapine at D2R, as it possesses the lowest efficacy 
with respect to these actions of APDs. Results displaying unique binding of clozapine to 
D2R harbor intriguing implications for APD discovery and development, and provokes 
novel speculative thought and questions on the nature of ligand-receptor interaction. 
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ABSTRACT 
Clozapine is an antipsychotic drug (APD) with a uniquely efficacious therapeutic profile 
that is preeminent for treatment resistant schizophrenia.  A common property of all 
clinically available APDs is that they bind D2-like dopamine receptors at therapeutic 
concentrations.  However, unique molecular actions for clozapine that are different from 
all other APDs have not been established.  Here we show that treatment with all APDs 
upregulates cell-surface expression of D2-dopamine receptors (D2R), relative to that 
produced by clozapine.  Multiple experiments, including a pulse-chase assay for surface 
D2R indicated that the APD-mediated upregulation of D2R is due to enhanced insertion of 
D2R into the plasma membrane and not differences in receptor occupancy or protein 
synthesis.  The potency of amisulpride, an APD with poor membrane permeability, for 
upregulating surface D2R was increased by coexpressing OCT1, an amisulpride 
transporter, suggesting an intracellular site of action for APDs.  Competition experiments 
and experiments with a non-APD-binding D2R mutant indicated that APD upregulation of 
surface D2R is a consequence of direct receptor binding.  Enhancement by APDs of 
surface D2R, relative to that produced by clozapine, was magnified in both a 
glycosylation-deficient and a misfolding D2R mutant.  Moreover, every APD, except 
clozapine, enhanced the detergent solubility of intracellular D2R.  These and other data 
suggest that APDs act intracellularly as chemical chaperones to stabilize a conformation 
of D2R with enhanced detergent solubility and transport to the cell surface.  These results 
display a unique molecular event of clozapine at D2R, as it possesses the lowest efficacy 
with respect to these actions of APDs.    
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INTRODUCTION 
The development of antipsychotic drugs (APDs) beginning more than 70 years ago 
revolutionized the treatment of schizophrenia and related psychotic disorders (Tandon, 
2011a).  A common action of all clinically available APDs is that they bind D2-like 
dopamine receptors (D2-like DR) at therapeutic concentrations (Kapur and Mamo, 2003a; 
Kapur and Remington, 2001; Seeman, 2006; Urs et al., 2017).    
D2-like DR are members of the seven transmembrane domain G protein coupled 
receptor (GPCR) superfamily and, of the three D2-like DR (D2, D3 and D4) (Beaulieu et 
al., 2015; Vallone et al., 2000), the D2-dopamine receptor has the most widespread 
distribution in the brain (Beaulieu and Gainetdinov, 2011a; Missale et al., 1998).  
Alternative splicing produces two D2-dopamine receptor isoforms, D2 short (D2Rsh), and 
a longer form (D2R) which contains 29 additional amino acids inserted in the 3rd 
cytoplasmic loop (Beaulieu et al., 2015; Missale et al., 1998; Vallone et al., 2000).   
D2-like DR expressed in certain striatal neurons are important for the control of 
movement, and blockade of these receptors by APDs can produce both acute and 
“tardive” movement disorders collectively called extrapyramidal 
symptoms (EPS) (Dayalu and Chou, 2008; Meltzer, 2013a; Tandon, 2011a).  Acute 
symptoms include Parkinsonism, and chronic treatment may produce a potentially 
irreversible and debilitating movement disorder called tardive dyskinesia (TD).   
Schizophrenia symptoms may be organized into three groups: 1) positive symptoms such 
as hallucinations and delusions; 2) negative symptoms such as apathy and severely 
impaired social functioning; and 3) cognitive symptoms such as disorganized thought and 
inability to concentrate (Freedman, 2003a).  The early APDs, while effective at 
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suppressing positive symptoms, had limited efficacy against negative and cognitive 
symptoms (Meltzer, 2013a; Tandon, 2011a).   
The introduction of clozapine in the 1970s was a major milestone in the pharmacotherapy 
of schizophrenia because clozapine appeared to demonstrate superior efficacy against both 
positive and negative symptoms, with significantly minimized risk of acute EPS and TD 
relative to the older drugs (Casey, 1989a; Essali et al., 2009; Iqbal et al., 2003; Wenthur 
and Lindsley, 2013a).  However, clozapine-induced agranulocytosis and metabolic side 
effects that increase risk of cardiovascular morbidity have restricted the use of this highly 
effective APD (Iqbal et al., 2003; Naheed and Green, 2001; Opgen-Rhein and Dettling, 
2008).  The unique therapeutic profile of clozapine catalyzed efforts to develop safer 
drugs that replicate clozapine’s unique efficacy and produce fewer and less severe side 
effects.  Several 2nd-generation APDs were developed by searching for molecules that 
shared two pharmacological properties of clozapine which were unique relative to those of 
1st-generation drugs, namely 1) reduced binding affinity for D2-like DR, and 2) enhanced 
binding affinities for other brain receptor systems, particularly 5-HT2A serotonin 
receptors (Jibson and Tandon, 1998a; Kuroki et al., 2008a; Meltzer and Huang, 2008; 
Seeman, 2002).   
Nevertheless, evidence from both clinical trials and practice, reviewed in numerous 
manuscripts (Agid et al., 2008, 2010a; Kang and Simpson, 2010; Lewis and Lieberman, 
2008a; Manschreck and Boshes, 2007; Meltzer, 2012a; Tandon et al., 2008), indicate that 
clozapine outperforms all other APDs, both atypical 2nd generation and typical 1st 
generation APDs, with respect to nearly all aspects of schizophrenia pharmacotherapy.  
Further, clozapine treatment produces the greatest suppression of mortality in 
schizophrenia  (Agid et al., 2010a; Kerwin and Bolonna, 2004a; Meltzer, 2012a) and is 
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the first choice for treatment-resistant patients (Foussias and Remington, 2010; Meltzer, 
2012a, 2013a; Siskind et al., 2016).  Clozapine also has a uniquely favorable motor side-
effect profile as it is the least likely of the 2nd generation drugs to cause TD (Margolese et 
al., 2005) and is the only APD that has “level A” evidence to support its use in 
suppressing psychoses in Parkinson’s disease patients (Friedman, 2013).  A review by 
Meltzer states that “the advantages of clozapine which have emerged from controlled 
clinical trials have been borne out in clinical practice and in the often remarkable 
improvement noted in patients who have failed previous attempts at treatment” (Meltzer, 
2012a). Accordingly, clozapine has been referred to as the “gold standard” drug for the 
treatment of schizophrenia (Kang and Simpson, 2010; Meltzer, 2012a), but its adverse 
effects have restricted its use.   
The dopamine-serotonin antagonism theory (Meltzer et al., 2003) does not entirely explain 
the unique efficacy of clozapine, since this pharmacological property is shared with other 
2nd generation APDs.  Multiple alternative molecular actions for clozapine have been 
proposed to explain its distinctive efficacy, and these have been reviewed (Seeman, 2014; 
Wenthur and Lindsley, 2013a).  A partial list includes binding to subtypes of muscarinic 
acetylcholine receptors, adrenergic receptors, and glutamate receptors, “fast-off” binding, 
and low or transient occupancy of D2R at therapeutic concentrations (Seeman, 2014; 
Wenthur and Lindsley, 2013a).  However, each of these actions cannot explain the 
singularity of clozapine in schizophrenia because some or all are common to other APDs.  
For example, muscarinic and adrenergic receptor antagonism (Jibson and Tandon, 1998a), 
low D2R occupancy, and “fast off” D2R binding kinetics are properties shared by 
multiple 2nd generation APDs (Seeman, 2006).  It is conceivable that it is the set of 
quantified actions at all of these targets that is different between clozapine and all of the 
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other APDs, but a set unique to clozapine has yet not been clearly defined.  Alternatively, 
there may yet be undiscovered molecular actions of clozapine, which are clearly different 
from those of all other APDs, which could contribute to its unique efficacy.   
We recently reported (Sharma et al., 2013a) that D2R are functionally compartmentalized 
in the plasma membrane. On the basis of that observation, here we compared APDs with 
respect to their potential influences on plasma membrane D2R expression. We report here 
for the first time unique molecular actions of clozapine, compared to all other APDs 
tested, on D2R functional expression in HEK293 cells, a widely used experimental model 
of D2R function (Min et al., 2015; Namkung and Sibley, 2004a; Octeau et al., 2014; 
Sharma et al., 2013a; Thibault et al., 2011).  
RESULTS 
APD treatment enhanced cell-surface expression of D2R.  Concentration-response curves 
for APD-enhancement of cell-surface D2R expression were generated after 24 hr of 
treatment with a 1st-generation APD, haloperidol, a second-generation APD, olanzapine, 
and clozapine (Fig. 1).  As described in the Methods section, relative cell-surface levels of 
D2R, transiently expressed in HEK293T cells, were detected using an ELISA-based 
assay, which measured binding of the intact cells to an antibody targeted against the D2R 
construct.  The relative levels of surface D2R after APD treatment are reported as the 
percent increase in surface D2R expression over vehicle.  Treatment with all the three 
APDs significantly enhanced cell-surface D2R expression (Fig. 1A).   
Relative to the actions of clozapine, all APDs except aripiprazole significantly enhanced 
cell-surface expression of D2R.  We then performed a screen that compared the actions of 
a wider selection of APDs to that of clozapine on cell-surface D2R expression (Fig. 1B).  
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The maximal enhancement of cell-surface D2R expression produced by clozapine was 
achieved at a concentration of 10 µM.  This is also the concentration that produces close 
to saturation D2R-binding for all of the tested APDs, according to previously summarized 
affinity measurements for the cloned receptor construct in intact cells (Richtand et al., 
2007; Sahlholm et al., 2016).  Accordingly, all APDs were tested at 10 µM. 
Treatment with all APDs except aripiprazole produced significantly more D2R surface 
expression than the maximum that could be produced with clozapine treatment (Fig. 1B).  
Hence, we can conclude that all tested APDs, except for aripiprazole, are more efficacious 
than clozapine for enhancing cell-surface D2R expression.   
The greater enhancement of surface D2R expression produced by other APDs, relative to 
clozapine, could not be attributed to relatively greater enhancement of total cellular D2R 
expression.  A subset of the APDs, including haloperidol and clozapine, were tested for 
actions on expression levels of total cellular D2R (Fig. 1C).  The relative levels of total 
cellular D2R were measured using an ELISA assay, similar to that utilized above to 
specifically measure cell-surface receptor expression.  However, to measure relative levels 
of total cellular receptors instead, cells were fixed in methanol, so that both surface and 
intracellular pools of D2R were accessible to the D2R-detecting antibody.  Treatment with 
all tested APDs, including clozapine, but not aripiprazole, significantly enhanced total 
cellular D2R expression levels by at least 250%. Aripiprazole only enhanced D2R 
expression levels by about 125%. All other APD treatments were not significantly 
different from each other.  
Enhancement of surface D2R expression by haloperidol is a result of long-term APD 
treatment. All previous APD treatments in this study were done over a 24 hr period. To 
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test whether enhancement of cell surface D2R expression was truly an effect of long-term 
APD treatment, we measured relative levels of surface D2R expression following 6, 12, 
and 24 hr treatment, using haloperidol as a representative because it had displayed the 
most pronounced effect on D2R surface expression. Haloperidol-mediated enhancement 
of surface D2R expression increased from almost no effect after 6 hr to an increase of 
about 300% after 12 hr, to about 500% after 24 hr (Fig. 1D). Thus, APD-mediated 
enhancement of surface D2R expression appears to be a function of time; the longer the 
treatment the greater the effect. 
Compared to clozapine, both haloperidol and aripiprazole produced significantly greater 
enhancements of the rate of surface D2R insertion into the plasma membrane.  Loss of 
GPCRs from the cell surface may occur via sequestration (Rajagopal and Shenoy, 2017) 
or via in situ proteolysis and degradation.  Therefore, the amount of receptor at the cell-
surface is the difference between the rate of insertion and the rate of loss of the receptor 
from the plasma membrane.  Hence, by measuring the relative effect of APD treatments 
on the specific removal of D2R from the cell surface we attempted to discern whether the 
greater APD-induced enhancement of D2R surface expression, relative to that produced 
by clozapine, was a consequence of increased receptor insertion, decreased removal, or 
both.    
In order to evaluate the relative effects of APDs specifically on the removal of cell-surface 
D2R, we utilized a previously validated pulse-chase protocol (Kumagai et al., 2015), as 
described in the Methods section.  The protocol monitored the loss of a pre-biotinylated 
pool of HaloTag D2R, a D2R construct with an extracellular N-terminal insertion of 
HaloTag, from the cell surface.  The HaloTag insertion allows for the specific 
biotinylation of cell surface-expressed HaloTag D2R using a membrane-impermeable 
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Halotag-PEG-Biotin reagent.  After pre-biotinylation of cell surface-expressed HaloTag 
D2R, cells were treated with haloperidol, aripiprazole, or clozapine (10 µM, 24 hr).  The 
relative levels of HaloTag-PEG-Biotin-labeled D2R remaining at the cell surface after 
APD treatment were quantified by probing intact cells with HRP-conjugated streptavidin.  
Under these conditions, receptors that were newly inserted into cell surface during APD 
treatment were not detected and only pre-biotinylated receptors that remained at the cell 
surface during the course of APD treatment is measured.   
The rates of loss of surface D2R during haloperidol and clozapine treatment were similar, 
because levels of biotin-labeled D2R remaining at the cell surface were not significantly 
different between the haloperidol- and clozapine-treated cells (Fig. 2A).  Hence, it may be 
concluded that haloperidol’s enhancement of cell-surface D2R expression (Fig. 1B), 
relative to that of clozapine, was a consequence of an enhanced rate of insertion of D2R 
into the plasma membrane, and not to a retarded rate of removal. 
Compared to either haloperidol or clozapine treatment, aripiprazole treatment significantly 
lowered levels of pre-biotinylated D2R that remained at the cell surface (Fig. 2A). The 
observed enhanced sequestration or loss of D2R from the plasma membrane produced by 
aripiprazole was not surprising, since aripiprazole is a partial agonist at D2R with respect 
to recruitment of beta-arrestin, and may thus be expected to promote receptor 
endocytosis (Allen et al., 2011; Beaulieu and Gainetdinov, 2011a; Namkung and Sibley, 
2004a).  However, even though aripiprazole promoted a greater loss of cell-surface D2R 
than clozapine did (Fig. 2A), it did not produce lower cell-surface D2R levels (Fig. 1A). 
Therefore we can conclude that, of the two, aripiprazole must have produced a greater 
enhancement of the rate of insertion of D2R into the plasma membrane. 
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The ability of the pulse-chase biotinylation assay to reveal aripiprazole’s enhancement of 
sequestration of cell-surface HaloTag D2R (Fig. 2A) - even when total surface D2R 
levels are elevated (Fig. 1B) - supports the validity of utilizing the assay for comparing the 
specific loss of D2R from the cell surface. It also suggests that the HaloTag D2R and 
wild-type D2R function similarly.   
Nevertheless, the validity of utilizing the combination of the HaloTag D2R construct and 
the HaloTag-PEG-Biotin reagent to investigate the relative actions of APDs, specifically 
on D2R sequestration was further investigated in two control experiments.  Dopamine-
induced internalization is a well characterized phenomenon associated with D2R (Clayton 
et al., 2014; Gurevich et al., 2016). Here, we showed that dopamine treatment resulted in a 
loss of cell-surface HaloTag D2Rs (Fig. 2B).  This result added support to the view that 
HaloTag D2R and wild-type D2R respond to dopamine in a functionally similar manner. 
For the second control experiment, we investigated if the differential actions of the APDs, 
haloperidol and clozapine, on enhancing cell-surface D2R expression could be replicated 
in an assay that utilized the membrane impermeable HaloTag-PEG-Biotin reagent to 
measure the relative levels of cell-surface HaloTag D2R.  This experiment and subsequent 
investigations into the mechanisms of APD-induced upregulation of cell-surface D2R 
were limited to haloperidol and clozapine because they produced the greatest and least 
upregulation of cell-surface D2R, respectively, and thus served to model the full range of 
this action of APDs.     
HEK293T cells transiently expressing HaloTag D2R were first treated with either 
clozapine or haloperidol (10 µM, 24 hr).  The relative levels of cell-surface HaloTag D2R 
were then evaluated as described in the Methods section via biotinylation with HaloTag-
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PEG-Biotin reagent.  The pattern of action of haloperidol and clozapine treatment with 
respect to enhancement of surface D2R levels was similar to that obtained with the 
ELISA-based assay. Compared to clozapine treatment, haloperidol treatment resulted in a 
greater enhancement of cell-surface HaloTag D2R levels (Fig. 2C). 
APD-mediated cell-surface D2R upregulation is specific and consequent to D2R binding. 
We carried out further control experiments to determine the specificity of the response. In 
one, we found that neither haloperidol, nor clozapine produced surface upregulation of the 
β2-adrenergic receptor (β2AR) (Fig. 3A) or the mu-opioid receptor (MOR) (Fig. 3B).     
Previously, it has been shown that the mutant D2R, D2RD114A, does not bind agonists or 
antagonists (Han et al., 2009a; Xu et al., 1999).  In a second control experiment, we found 
that while D2RD114A expression was detected at the cell surface, neither cell-
surface (Fig. 3C) nor total cellular levels (Fig. 3D) of the mutant receptor was upregulated 
by treatment with either haloperidol or clozapine.  These data support the view that APD-
induced upregulation of cell-surface D2R is a consequence of specific binding to D2R.   
Treatment with haloperidol, but not clozapine, alters cellular co-localization of D2R with 
an ER marker.  Multiple studies from different laboratories have reported that the majority 
of D2R is atypically localized in intracellular perinuclear compartments, whether they are 
expressed across different cell lines, including HEK293, COS, HeLa, CHO, and 
NG108 (Fishburn et al., 1995a; Kovoor et al., 2005a; Prou et al., 2001a; Sharma et al., 
2013a), or endogenously expressed in neurons (Kim et al., 2008a; Kovoor et al., 2005a; 
Tirotta et al., 2008a).  Furthermore, one study showed that these compartments were 
labeled by an endoplasmic reticulum (ER) marker (Prou et al., 2001a).  The molecular 
basis for the anomalous cellular localization of D2R was recently identified (Kubale et al., 
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2016a). A di-arginine motif can function as an ER retention signal, and it was shown that 
a conserved arginine cluster in the 3rd cytoplasmic loop of D2R (residues 267, 268 and 
269) functions as such a signal for D2R (Kubale et al., 2016a).   
As predicted by previous reports, we found in our lab, using confocal microscopy that the 
vast majority of D2R co-localized with the general ER marker, mCh-Sec61 beta (Fig. 4A).  
Treatment with haloperidol, but notably not clozapine, resulted in: 1) the emergence of a 
ring of D2R signal that coincided with the cell boundaries and, 2) significantly decreased 
D2R-mCh-Sec61 beta co-localization.  
The particular D2R tri-arginine ER retention signal identified above, D2RR267, 268,269,is not 
present in the shorter alternatively spliced, D2Rsh isoform, and previously it has been 
shown that D2Rsh is retained in the ER to a lesser degree than D2R (Prou et al., 2001a).  
Therefore, we compared the actions of haloperidol and clozapine treatment on cell-surface 
levels of D2Rsh. The aim was to determine whether the two APDs act differently to up-
regulate cell-surface receptors with greater and lesser ER retention. Indeed, treatment with 
haloperidol, but not clozapine increased cell-surface D2Rsh levels and, to a lesser extent, 
levels of D2R (Fig. 5A). This is not unexpected, because D2Rsh is less encumbered in 
trafficking to the cell surface, and should display higher surface expression in vehicle-
treated cells. Nevertheless, haloperidol did produce some upregulation of D2Rsh. We next 
tested whether these differences between the effects of haloperidol and clozapine were not 
a consequence of differences in the processes of total cellular D2Rsh upregulation.  We 
compared the effects of haloperidol and clozapine on total D2Rsh in the same manner as 
we did on levels of D2R. Both haloperidol and clozapine similarly increased total D2Rsh 
expression, relative to vehicle, by about 50% (Fig. 5B).  
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Increased surface D2R expression induced by amisulpride, but not tiapride, is enhanced 
by OCT1. We then asked whether the key interaction between the APDs and D2R that 
results in the upregulation of surface receptor occurs at the cell membrane or 
intracellularly. Amisulpride is an APD with poor membrane permeability, and is a 
substrate for the membrane transporter OCT1 (Dos Santos Pereira et al., 2014). As 
previously mentioned, direct binding of APDs to D2R is required for APD-induced 
increases in surface D2R expression. If this key specific interaction occurs intracellularly, 
then amisulpride’s potency for inducing increased expression of surface D2R should be 
enhanced by co-expression of OCT1, because more surface OCT1 should result in more 
amisupride's entering the cell. To answer this question, we generated concentration-
response curves for amisulpride’s ability to increase surface D2R expression in the 
presence and absence of OCT1. HEK293T cells expressing D2R with and without OCT1 
co-expression were treated with increasing concentrations (10-10,000 nM) of amisulpride.  
We found that OCT1 co-expression greatly enhanced amisulpride’s effect, reducing its 
EC50 from 663 nM to 10 nM, with the maximum effect attained at an amisulpride 
concentration 100X lower than that of OCT1-deficient cells (Figure 6A). This shift to the 
left in amisulpride’s dose-response curve indicates that transport into the cell is necessary 
for its effect, and provides evidence that the key interaction leading to APD-induced 
enhanced surface D2R expression occurs intracellularly.  
 
In a control study, we repeated the experiment with tiapride, another APD with poor 
membrane permeability that is not a substrate for OCT1. Here we saw no change in 
tiapride’s effect with OCT1 co-expression (Figure 6B). Therefore, these data suggest that 
it was specific transport of amisulpride into the cell by OCT1 that enhanced its effect on 
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D2R surface expression. Thus, entrance into the cell is critical for APD-mediated 
enhancement of D2R surface expression, and the key interaction is intracellular.   
 
Haloperidol rescues misfolded receptor for export to the cellular membrane. Several 
studies have reported on the ability of ligands to overcome ER-retention motifs, and 
rescue misfolded receptors, to promote their export from intracellular membranes to the 
cell surface in a process known as pharmacochaperoning (Lan et al., 2012; Lester et al., 
2012; Wüller et al., 2004). Since we have shown that APDs can overcome D2R’s tri-
arginine ER retention motif to enhance their cell surface expression of D2R, we then 
asked whether APDs could rescue misfolded protein for export to the plasma membrane. 
Previous reports have utilized misfolding GPCR constructs, made by mutating a single 
conserved tryptophan residue, to investigate ligand pharmacochaperone capabilities and 
their proficiency in rescuing misfolded receptor for export to the plasma membrane (Lan 
et al., 2012). We utilized a D2RW160A mutant, with a point mutation at the conserved 
tryptophan residue that misfolds, and displays no significant membrane receptor 
expression, to assess the ability over APDs to rescue misfolded D2R for export to the cell 
surface. Cells treated with haloperidol displayed enhanced surface D2RW160A 2000% 
relative to vehicle, while clozapine was barely able to raise the signal above background 
(Fig 7A). Vehicle treated cells displayed no surface signal above background. To control 
for differences in total D2RW160A signal, we then assessed effects of clozapine and 
haloperidol treatment on total D2RW160A expression as described in previous experiments. 
While all cells transfected with D2RW160A cDNA displayed significant total D2RW160A 
expression over background, neither clozapine nor haloperidol treatment significantly 
increased total receptor expression relative (Fig 7B). Thus, haloperidol is capable of 
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rescuing misfolded D2R for insertion into the plasma membrane and displays strong 
pharmacochaperone capabilities, while clozapine does not.  
 
Haloperidol enhances membrane insertion of a glycosylation-deficient D2R mutant.It is 
well established that post-translational modification (PTM) of GPCRs along the excretory 
pathway greatly contributes to proper membrane expression (Dong et al., 2007). A PTM 
of particular importance for membrane expression of D2R is N-linked glycosylation at the 
N-terminus (Min et al., 2015). We determined whether APD treatment could enhance the 
membrane insertion an N-linked glycosylation-deficient D2R, a D2R construct even 
further restricted from cell surface expression. This mutant, D2RN5,N17,N23→Q was created 
by causing three point mutations (N 5, 17,23 Q) to remove N-linked glycosylation. We 
assessed the effect of APD treatment on the surface expression of D2RN5,N17,N23→Q  in the 
same manner as described above. Both haloperidol and clonidine substantially increased 
the total expressions of D2RN158A(Figure 7C) and D2RN5,N17,N23→Q (Figure 7E), but only 
haloperidol increased the cell-surface levels of  D2RN5,N17,N23→Q (Figure 7D). Thus, the 
efficacy of haloperidol and lack of efficacy of clozapine as pharmacochaperones of D2R 
is highlighted by D2R mutants that are further restricted from membrane insertion.  
Haloperidol treatment increases detergent solubility of total D2R. We previously reported 
that D2R segregates predominantly into Triton X-100 insoluble biochemical fractions 
(Octeau et al., 2014; Sharma et al., 2013a). We also reported that dopamine treatment 
reduced the amount of Triton X-100 insoluble D2R expressed at the plasma membrane 
(Sharma et al., 2013a). Our lab has previously shown that D2R detergent solubility can be 
altered by APD treatment (Octeau, 2014). Therefore we asked what effect specifically 
haloperidol and clozapine treatment could have on the biochemical profile of D2R. 
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HEK293T cells expressing D2R were treated with receptor-saturating concentrations of 
the indicated APDs, and the TX-100-soluble and insoluble fractions of D2R were isolated 
and receptor expressed in each was measured as described in the Materials and Methods. 
Treatment with haloperidol significantly increased the detergent solubility of D2R, while 
clozapine did not (Fig 8B). In fact, clozapine decreased the detergent solubility of D2R 
with respect to vehicle. Thus we conclude that the APDs, except clozapine, efficaciously 
increase the detergent solubility of D2R, while clozapine is the only drug that decreases 
the detergent solubility. 
Intracellular D2R restricted from interacting with ER marker PTP1B evidenced by BRET 
ratios. Previous studies have reported that detergent-insolubility can be characteristic of 
aggregated proteins (Basso et al., 2009; Schlager et al., 2012; Shaw et al., 2008). Because 
clozapine increases the detergent insolubility of intracellular D2R, we further 
characterized this receptor pool and investigated the possibility that ER-targeted D2R is 
aggregated. Based on the aforementioned PCCs and confocal images in ICC, we know 
that D2R predominantly co-localizes with ER marker Sec61 (Fig 4). However, though it 
may display co-localization, aggregated protein may not be able to interact functionally 
with other nearby proteins. To assess D2R’s ability to interact with other ER targeted 
proteins, we utilized bioluminescent resonance energy transfer (BRET). We compared the 
ability of D2R fused with Renilla-luciferase (D2R-Rluc8) to participate in BRET with ER 
marker PTP1B with other cell surface and ER targeted GPCRs. Previously, the trafficking 
β2-adrenergic receptor (β2-AR) was compared with a misfolding β2-AR mutant, β2-
ARW158A via BRET with the PTP1B (Lan et al., 2012). It was reported that, based on the 
calculated BRET ratios occurring between each receptor construct and PTP1B, wild type 
β2-AR displayed much greater membrane expression, while β2-ARW158A was indeed 
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retained in the ER (Lan et al., 2012). We performed ICC and obtained confocal images of 
the cellular localization β2-AR and β2-ARW158A. Here we show dramatic cell surface 
expression of β2-AR, while β2-ARW158A displays predominant co-localization with the 
ER-marker Sec61 (Fig 9A); this pattern is similar to that of D2R. This provided an 
opportunity to compare BRET efficiencies of two heavily membrane-targeted and ER-
retained GPCRs belonging to different classes. As described in the Materials and Methods 
section, we measured BRET ratios occurring between PTP1B-Venus and either D2R-
Rluc8, β2-AR-Rluc8, or β2-ARW158ARluc8. BRET ratios calculated between PTP1B-
Venus and β2-AR-Rluc8 represent the level of BRET occurring between an ER targeted 
marker, and a membrane targeted receptor with almost no ER co-localization. BRET 
ratios calculated for each of the three receptors were expressed as a percentage of the 
calculated BRET ratio for β2-AR (Fig 9B). β2-ARW158A displayed a much higher BRET 
ratio than β2-AR (Fig 9B), which is expected because it also exhibits much higher ER 
localization. Interestingly, D2R resulted in the lowest BRET ratio with PTP1B, despite 
displaying high ER localization (Fig 9B). In other words, D2Rs and β2-ARs exhibit 
contrasting distributional and interactive characteristics. D2Rs are localized 
predominantly in the ER while β2-AR are found mainly in the plasma membrane, but 
D2Rs interact with ER-targeted proteins less than β2-ARs do. This suggests that D2R 
located in the ER may not functionally interact with other ER targeted proteins, thus and 
may be non-functional aggregated protein in the ER. Furthermore, since clozapine 
increases D2R total expression and detergent insolubility - without altering the solubility 
and only slightly affecting the expression of total surface D2Rs - it could actively promote 
the accumulation of insoluble, aggregated, non-interacting D2Rs in the ER. None of the 
other APDs seem to display this ability.  
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PTX co-expression lowers APD-mediated enhancement of surface D2R expression. We 
then explored the effect of G-protein inhibition on APD-induced enhancement of surface 
D2R expression. HEK293T cells were co-transfected with cDNAs for D2R and PTX, and 
treated with receptor-saturating concentrations of haloperidol, clozapine, or vehicle for 
24 hr. Both haloperidol and clozapine were able to increase surface expression of D2R, 
and haloperidol-treated cells exhibited significantly higher surface D2R expression than 
those treated with clozapine (Fig 10A). Interestingly, the effect of haloperidol was 
dramatically reduced in cells co-expressing PTX relative to those expressing D2R alone, 
suggesting that G-protein inhibition reduces the ability of APDs to enhance surface 
expression of D2R. 
Enhancement of surface D2R expression effect on G-protein signaling. In order to 
investigate the effect of increased surface D2R expression on G-protein activation, we 
utilized BRET to measure agonist-induced recruitment of G-protein receptor kinase 
(GRK) following 24 hr APD treatment as described in Materials and Methods. Measuring 
G-protein activation in this manner has been previously described and validated 
(Donthamsetti et al., 2015). BRET can only occur between the Gβγ subunit and GRK3 
once the receptor has been activated by the agonist and G-proteins dissociate. HEK293T 
cells transiently expressing D2R, Gαi, Venus 155-239 Gβ1, Venus 155 Gγ2, and the 
masGRK3ct NanoLuc were treated with receptor-saturating concentrations of haloperidol, 
clozapine, or appropriate vehicle for 24 hr. To wash away APDs following treatment, cells 
were incubated with drug-free medium for 2 hr, and then washed 3x in 1XPBS. Net BRET 
between activated G-proteins and recruited GRK3 was calculated by subtracting the 
measured BRET ratio before the addition of agonist to the measured BRET ratio 
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following the addition of agonist. A dose-response curve for dopamine-induced activation 
of D2R-coupled G-proteins was generated, reaching maximum responses at ~100 nM 
dopamine (Fig 10B). Unfortunately, we were unable to obtain a dopamine response in 
APD treated cells even at dopamine concentrations of 10 μM. Thus, we conclude that an 
inability to wash out the APDs following prolonged treatment prevents us from measuring 
agonist-induced G-protein activation by this method. 
DISCUSSION 
APDs act as active pharmacochaperones of D2R. Several  studies have reported on the 
ability of ligands to act as pharmacochaperones for cell surface receptors (Lan et al., 2012; 
Lester et al., 2012; Wüller et al., 2004) by facilitating cellular receptor inter-
compartmental translocation. These pharmacochaperones can serve to both rescue 
misfolded receptors, and to overcome coded ER retention signals to produce enhanced 
export trafficking of GPCRs (Lan et al., 2012; Lester et al., 2012; Wüller et al., 2004). It is 
well established that prolonged treatment with antagonists in animals can result in GPCR 
upregulation (Millan et al., 1988; Unterwald et al., 1995). We have conclusively shown 
here that APD treatment can actively enhance membrane insertion of D2R in the absence 
of agonist. With the exception of partial agonists like aripiprazole (Burris et al., 2002; 
Frankel and Schwartz, 2017), APDs are considered antagonists of D2R, and are thus 
assumed to have no intrinsic activity (Boyd and Mailman, 2012; Meltzer, 2013b; 
Sahlholm et al., 2014). Here we also present the first evidence that APD binding of D2R 
activates a cellular signal. The data presented in figure 1A-B clearly show that APD 
treatment enhances surface D2R signal relative to vehicle-treated cells, with clozapine 
treatment producing significantly less surface D2R expression than the other APDs. As 
shown in figure 1C, total D2R expression was similarly influenced by all tested APDs 
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(except aripiprazole), indicating that enhanced surface expression was not simply a result 
of increased total D2R expression. Results of the Halo-D2R experiments show that 
surface D2R degradation rates were not different in APD- and vehicle-treated cells. Thus, 
differences in surface receptor levels produced by APDs are a result of increased 
membrane insertion and not reduction in surface receptor degradation.  
 
APD-induced membrane insertion of D2R is a result of direct, specific binding to the 
receptor, because APD-mediated effects on both surface and total D2R are diminished in 
the ligand-binding-deficient D2RD114A mutant (fig 3C-D). Confocal images and PCCs 
derived from ICC, as depicted in figure 4, display haloperidol’s ability to cause a 
redistribution of D2R from the ER to the plasma membrane, overcoming D2R’s naturally 
coded ER retention. Surface expression of D2Rsh, which lacks the tri-arginine ER 
retention motif of D2R, is less affected by haloperidol treatment because they are already 
more extensively distributed on the cell surface. This further suggests that haloperidol is 
able to overcome ER retention signals of D2R. The shift in the dose-response curve of 
poorly membrane soluble amisulpride, in the presence of OCT1, indicates that the location 
of the key interaction for APD-enhanced membrane insertion occurs intracellularly (fig 6). 
Haloperidol also displays the ability to rescue the misfolded D2RW160A mutant and 
mediate its membrane insertion, which is otherwise completely absent (fig 7). As protein 
folding and handling of misfolded protein, largely occur in the ER, this is further 
indication that the site of key interaction is not only intracellular, but also takes place in 
the ER. From this data, we reasonably conclude that in addition to blocking D2R-mediate 
G-protein signaling at the cell surface, APDs bind D2R intracellularly and overcome 
receptor misfolding and natural ER retention, to actively enhance membrane insertion of 
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D2R. Thus, APDs have intrinsic activity as active pharmacochaperones of D2R, and 
should be considered agonists for this effect.  
 
Clozapine binding stabilizes D2R in a unique conformation, and displays unique 
molecular action at D2R. As previously mentioned, it has been extensively reported that 
clozapine, in practice and in numerous clinical studies, out performs all other APDs in 
effectively treating both the positive and negative symptoms of schizophrenia (Agid et al., 
2010b; Lewis and Lieberman, 2008b; Meltzer, 2012b; Tandon R et al., 2007). 
Hypothesized explanations for clozapine’s superior efficacy arising from action at 
receptors other than D2R, such as muscarinic or adrenergic receptors, have fallen short, as 
these binding characteristics are shared by many of the other APDs (Jibson and Tandon, 
1998b). As a result, many researchers are returning to the belief that action at D2R is 
essential for APD efficacy (Kapur and Mamo, 2003b). Here we present the first evidence 
of unique molecular actions of clozapine at D2R. The dose-response curves depicted in 
figure 1A clearly show clozapine’s pharmacochaperone effects on D2R saturating at 
higher concentrations and only producing 35% of haloperidol’s efficacy. Comparison with 
a wide array of other APDs revealed that long-term treatment with clozapine produced 
significantly less surface D2R expression than any of the other tested APDs except 
aripiprazole (Figure 1B). Evaluation of total D2R expression among indicated APD 
treated groups (Figure 1C) revealed similar increases in total D2R expression after 
treatment and other APDs, including haloperidol, indicating that the observed lower 
surface D2R expression in clozapine-treated cells was not a function of lower total 
receptor signal in those cells. As previously discussed, we have shown that the APD-
induced enhancement of surface D2R is a result of enhanced membrane insertion of the 
receptor. Replacing with the ligand-binding deficient D2RD114A mutant, diminishes effects 
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of both clozapine and haloperidol, indicating a like binding site for clozapine and the other 
APDs (fig 3C-D). Although, aripiprazole or clozapine treatment results in similar levels of 
surface D2R, aripiprazole-treated cells display dramatically less total D2R (fig 1C) and 
higher rates of surface D2R degradation (fig 2A) when compared with clozapine. Thus, 
for aripiprazole treatment to result in similar levels of surface D2R expression to that of 
clozapine, it must induce a higher rate of membrane insertion of D2R relative to that of 
clozapine. Therefore, we have clearly shown that in the absence of agonist, all tested 
APDs, including aripiprazole, enhance membrane insertion of D2R relative to clozapine.   
Confocal images and PCCs derived from ICC experiments reveal that, unlike haloperidol, 
clozapine does not cause redistribution of D2R from the ER to the cell membrane. 
Furthermore, co-treatment with clozapine resulted in blockade of haloperidol-mediated 
increases in surface D2R, indicating that while they are binding in the same location, 
clozapine and haloperidol are producing, in the absence of agonist, distinct effects at D2R. 
Clozapine was unable to reproduce haloperidol’s ability to rescue misfolded D2RW160A for 
efficient surface expression, despite resulting in similar total receptor signal. Thus, 
haloperidol can stabilize the misfolded D2R in a conformation suitable for membrane 
insertion while clozapine cannot, further highlighting the existence of distinct binding 
confirmations for the two drugs.   We have previously shown that treatment with all tested 
APDs, except for clozapine, increases the detergent solubility of D2R (Octeau, 2014). 
Here, again, we show that while haloperidol treatment dramatically increases the detergent 
solubility relative to vehicle, clozapine treatment does not. Further, the data suggests that 
clozapine may in fact increase the detergent insolubility of D2R, but the effect is not 
statistically significant. Binding by all tested APDs, except for clozapine, significantly 
alters the biochemical properties of D2R. Thus we have unequivocally shown that 
although all the tested APDs share a common D2R binding site, only clozapine induces a 
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completely unique binding conformation of D2R, as evidenced by its distinct actions at 
the receptor. This is the first evidence of unique molecular actions of clozapine at D2R. 
 
D2R ER retention and drug effective doses highlight physiological relevance. A common 
criticism of studies such as this is that drug doses used exceed physiologically relevant 
concentrations.  It seems that such concerns do not apply here, because APD 
concentrations have been measured in the 1-5 μM range in both human and rat brains 
(Baldessarini et al., 1993; Froemming et al., 1989; Kornhuber et al., 2006).  Further, the in 
the dose response curves shown in figure 1B, response maxima are achieved at 
concentrations in the 0.1 – 3 μM range, comparable to the in-brain measured 
concentrations. 
 
It seems unlikely that either the observed intracellular distribution of D2R or possible 
protein misfolding is an artifact of overexpression in HEK293 cells.  However, as 
previously stated, this pattern of distribution is typical of D2R in a variety of models and 
cell types (Fishburn et al., 1995b; Kovoor et al., 2005b; Prou et al., 2001b; Sharma et al., 
2013b).  Additionally, the tri-arginine motif found in the 3rd intracellular loop of D2R has 
been reported to target D2R to the ER. Hence, the intracellular accumulation of D2R 
observed here would be expected, as it appears naturally coded to do so.  As previously 
stated, D2Rsh is a splicing variant of D2R, lacking 29 amino acids within the 3rd 
cytoplasmic loop, including the A267-269 tri-arginine ER retention motif in D2R long 
isoform.  Since the intracellular localization of D2R has been shown to be heavily 
influenced by the A267-269 ER retention motif, it is not surprising that D2sh, which lacks 
this motif, displays much greater surface expression (Prou et al., 2001b). It has also been 
reported that actions of pharmacochaperones include overcoming ER retention signals to 
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promote export of transmembrane receptors to the cell surface (Wüller et al., 2004). If, as 
we propose, APDs are acting as pharmacochaperones, and, as has been reported, D2R 
contains a strong ER retention motif that D2Rsh lacks, then APD treatment should have a 
much greater effect on the surface expression of D2R long isoform than D2Rsh.  This is 
exactly what we observed. The haloperidol-induced increase of surface D2Rsh was only 
half that of its effect on D2R. While clozapine increased surface expression of D2R by 
60%, it did not alter surface D2Rsh expression.  Therefore, we conclude that our observed 
intracellular, perinuclear expression of D2R is not an artifact of overexpression.  
Moreover, this highlights the physiological relevance of our finding, as D2R is 
endogenously coded for ER targeting, and APD treatment drastically alters that 
distribution. 
 
Repeatability with multiple detection methods confirm results are not artifacts of the 
detection methodology. Recently, it has been reported that sulfation of N-terminus linked 
FLAG epitope-tagged D2R greatly reduces binding of Anti-FLAG M2 antibody (Hunter 
et al., 2016), and that surface D2R expression was underestimated because of increased 
FLAG epitope sulfation.  Thus, some might argue that our observations are simply a 
function of APDs effecting FLAG-epitopte post-translational modifaction, specifically its 
sulfation, rather than pharmacochaperone effects on D2R itself.  We believe this is not the 
case for two reasons. First, the experiments revealing the differences in FLAG D2R 
recognition because of sulfation were done in HEK293 cells stably expressing FLAG 
D2R (Hunter et al., 2016).  Therefore, total D2R expression levels were dramatically 
lower than in our model, and any differences in receptor recognition observed based on 
sulfation would be much more dramatic than in our system. Secondly, we have repeated 
the initial observation - done with Anti-FLAG M2 antibody - with multiple detection 
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methods.  The Halotag experiments (Figure 2) utilize covalent linkage of PEG-biotin 
reagent, probed for with HRP-conjugated streptavidin, which cannot be explained away 
by FLAG-epitope sulfation.  ICC experiments, completed in our lab, using D2R fused to 
yellow fluorescent protein display the same punctate, intracellular, and perinuclear 
distribution of FLAG D2R labeled with fluorophore-conjugated anti-FLAG M2 
antibody (data not shown).  Thus, we have repeated observations acquired with anti-
FLAG M2 antibody with multiple detection methods, suggesting that the pattern of D2R 
localization we observe is not a function of differences in post-translation modification of 
the FLAG epitope. 
 
Implications. Perhaps the unique binding interaction of clozapine with D2R that we report 
here contributes to its superior clinical efficacy.  The concept of ligand bias, where ligands 
bind the same receptor, but produce distinct conformational changes resulting in selective 
receptor signal activation, has been observed for quite some time (Drake et al., 2008; 
Erickson et al., 2013; Luttrell, 2014; Makita and Iiri, 2013; Violin and Lefkowitz, 2007).  
Here we report for the first time that APDs are pharmacochaperone agonists for the 
promotion of D2R membrane insertion, as well as antagonists of endogenous ligand-
induced G-protein signaling. Thus, we have displayed the ability of APDs to activate 
cellular signals not yet considered. Of all of the APDs that we tested, clozapine displayed 
the least pronounced intrinsic activity as a pharmacochaperone of D2R, and clearly 
displays unique binding interactions with the receptor. Perhaps, clozapine’s seemingly 
bias-ligand binding profile, antagonizing D2R-mediated G-protein signaling while 
avoiding the pharmacochaperone effects of the other APDs is the key to its superior 
clinical efficacy. It is possible that the unique binding of clozapine to D2R either 
propagates or preserves cellular signals that the other APDs do not. If so, these findings 
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harbor great potential for the future of schizophrenia pharmacotherapy.  As previously 
mentioned, because of the fatal agranulocytosis produced by clozapine, its utility and 
impact in the treatment of schizophrenia is drastically limited (Farooq and Taylor, 2011; 
Pirmohamed and Park, 1997).  However, these results potentially provide a model for 
APD development, in which investigational compounds can be compared to clozapine to 
reproduce these observed unique receptor-ligand interactions, while avoiding 
agranulocytosis.  Maybe these results are the basis for the development of safe and 
tolerable antipsychotics that, like clozapine, effectively treat all aspects of schizophrenia.  
MATERIALS AND METHODS 
All reagents were purchased from Sigma-Aldrich (St. Louis, MO) or Thermo Fisher 
Scientific (Waltham, MA) unless otherwise indicated.    
Cell Culture. HEK293T cells (American Type Culture Collection, Manassas, VA) were 
cultured in Dulbecco’s modified Eagle’s medium (DMEM) with 10% fetal bovine serum 
supplemented with penicillin and streptomycin, and grown at 37 °C and 5% CO2.  cDNA 
transfections were performed with Lipofectamine LTX according to the manufacturer’s 
guidelines.  Transfected DNA amounts were kept constant between groups using empty 
pcDNA 3.1 Zeo (+) plasmid vector.  
cDNA Constructs. The N-terminal FLAG epitope tagged D2R (FLAG-D2R) long isoform 
and the N-terminal FLAG epitope tagged mu opioid receptor (FLAG-MOR) (Celver et al., 
2012a), the β2-adrenergic receptor RLuc8 fusion (β2AR-RLuc8), the β2ARW158A-RLuc8, 
and V-PTP1b (Lan et al., 2012), the FLAG-D2RT225,S228,S229A (Celver et al., 2013), the 
Venus 155-239 Gβ1, Venus 155 Gγ2, and the masGRK3ct NanoLuc (Masuho et al., 
2015), the OCT1 transporter (Boxberger et al., 2014), the N-terminal FLAG epitope 
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tagged β2AR (Hanyaloglu et al., 2005), the endoplasmic reticulum marker mCh-
Sec61 beta (Zurek et al., 2011a), and the catalytic subunit of pertussis toxin-GFP 
fusion (Celver et al., 2010) have been previously described.   
The HaloTag-D2R fusion consisted of the N-terminal influenza hemagglutinin signal 
sequence (MKTIIALSYIFCLVFA) followed by the FLAG epitope (DYKDDDDA), a two 
amino acid linker (TV) linker and the HaloTag enzyme (Los et al., 2008a) (Promega, 
Madison, WI) tethered to the N-terminus of D2R via a 3 amino acid linker (AAG).  Thus, 
the FLAG-HaloTag-D2R construct consisted of, in order from the N to the C terminus, the 
influenza hemagglutinin signal sequence epitope, FLAG epitope, TV linker, HaloTag, 
AAG linker, and the human D2R long isoform.  The FLAG-D2Rsh fusion was 
constructed by fusing the influenza hemagglutinin signal sequence and FLAG epitope to 
the N-terminus of the human D2R short isoform.  The FLAG-D2R-RLuc8 construct was 
made by fusing the Renilla Luciferase mutant, RLuc8, to the C-terminus of the Flag-D2R.  
For the FLAG-D2RN5,N17,N23Q, the FLAG-D2RD114A and the FLAG-D2RW158A mutants, 
the mutations refer to mutations in residues numbered as in the non-tagged wild type 
human D2R long form.  
Measurement of surface and total cellular FLAG-tagged receptor expression by ELISA 
with anti-FLAG antibody.  To evaluate the effect of APD treatment on cell-surface 
expression of receptor, we employed a previously well characterized ELISA-based 
protocol that utilized anti-FLAG antibodies to specifically label FLAG-tagged receptors 
expressed on the surface of fixed non-permeabilized cells (Celver et al., 2010; Daigle et 
al., 2008; Walker et al., 1999).  On day 1, HEK293 cells were seeded in a 96-well 
plate (5x104 cells/well) and transfected with plasmid vectors with cDNAs for the indicated 
FLAG-tagged receptor.  24 hr post-transfection, cells were treated with the specified 
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drugs, or corresponding vehicle, at the indicated concentrations, and for the indicated 
durations (usually 24 hr).  After drug-treatment, cells were fixed with 4% v/v methanol-
free paraformaldehyde (Electron Microscopy Sciences, Hatfield, PA) in phosphate-
buffered saline (PBS) for 15 min at 4 °C, and then washed 2x with PBS.  Wells were 
blocked for 1 hr at 4 °C with 5% w/v nonfat milk dissolved in PBS.  The levels of FLAG-
tagged surface receptor were then assessed by probing with horse radish 
peroxidase (HRP)-conjugated mouse monoclonal anti-FLAG M2 antibody (1:5,000 
dilution in 5% w/v nonfat milk dissolved in PBS) for 45 min at 20 °C, and then washed 2x 
in PBS.  Supersignal West Femto chemiluminescent substrate (Pierce-ThermoFisher 
Scientific) was added to each well, and the luminescence signal was measured using a 
Glomax luminometer (Promega).   
Total FLAG-tagged cellular receptor was evaluated in a similar manner, except that cells 
were fixed and permeabilized in 100% methanol (10 min, −20 °C) to allow antibody 
access to intracellular receptor. Subsequent washing, blocking, and antibody probing steps 
were identical to those described above.   
Dose response curves for clozapine, haloperidol, olanzapine, amisulpride or tiapride-
induced enhancement of surface D2R were generated by measuring surface receptor as 
described above.  Effects of OCT1 co-expression on dose-response curves were tested by 
co-transfecting cDNA for the OCT1 transporter with that for FLAG-D2R.   
Pulse-chase assay for specifically monitoring loss of cell-surface D2R.  This assay has 
been previously validated and used to track endocytosis of G protein coupled 
receptors (GPCR) via pulse-chase biotinylation specifically of the cell-surface expressed 
GPCRs (Kumagai et al., 2015).  HEK293T cells were seeded in 10 cm diameter culture 
29 
 
dishes, 2 × 106 cells per dish, transfected with HaloTag-D2R cDNA.  The HaloTag D2R 
fusion construct is described above and contains HaloTag inserted at the extracellular N-
terminus of D2R.  HaloTag is a modified bacterial enzyme designed so that it may be 
specifically and covalently tagged by a wide variety of synthetic probes (Los et al., 
2008a). 24 hr post-transfection, cell-surface HaloTag D2R was specifically biotinylated 
by incubating with the membrane-impermeable Halotag-PEG-Biotin reagent (100 nM in 
complete DMEM, 1 hr, 37 °C).  Cells were then washed 2x with 1X PBS, to remove 
unreacted Halotag-PEG-Biotin reagent, seeded in a 96-well plate at a cell number of 
160,000 cells/well and treated with 10 μM haloperidol, clozapine, aripiprazole, or vehicle.  
Following 24 hr of APD treatment, cells were fixed in 4% methanol-free 
paraformaldehyde (v/v in 1X PBS, 15 min, 4 °C) and then washed 2x in 1X PBS.  Wells 
were blocked with 3% BSA (w/v in 1X PBS) for 45 min at 20 °C.  Biotinylated HaloTag 
receptor remaining at the cell-surface receptor was detected using horseradish-
peroxidase (HRP)-conjugated streptavidin (1:10,000 dilution in 3% w/v BSA dissolved in 
1X PBS).  Supersignal West Femto chemiluminescent substrate was added to each well, 
and the HRP-catalyzed luminescent signal was detected and quantified using the Glomax 
luminometer. 
Measurement of the effect of APD treatment on total cell-surface HaloTag D2R with 
HaloTag-PEG-Biotin reagent.  Day 1 HEK293 cells were seeded in a 96 well plate at a 
density of 5x104, and transfected with Halotag D2R cDNA.  24 hr post-transfection, cells 
were treated with 10 μM haloperidol, clozapine, or vehicle.  Following 24 hr of APD 
treatment, and prior to fixation, total cell-surface receptor was specifically biotinylated by 
incubating with the membrane-impermeable Halotag-PEG-Biotin reagent (100 nM in 
complete DMEM, 1 hr, 37 °C).  Unreacted reagent was removed by washing 2X with 
30 
 
complete DMEM.  Cells were then fixed in 4% methanol-free paraformaldehyde (v/v in 
1X PBS, 15 min, 4 °C) and then washed 2x in 1X PBS.  Wells were blocked with 3% 
BSA (w/v in 1X PBS) for 45 min at 20 °C.  Biotinylated HaloTag receptor at the cell-
surface was detected using horseradish-peroxidase (HRP)-conjugated 
streptavidin (1:10,000 dilution in 3% w/v BSA dissolved in 1X PBS).  Supersignal West 
Femto chemiluminescent substrate was added to each well, and the HRP-catalyzed 
luminescent signal was detected and quantified using the Glomax luminometer. 
Measurement of agonist-induced Halotag D2R internalization. To assess its functionality, 
we tested the ability of the Halotag D2R fusion to internalize using a variation of the same 
ELISA-based technique in a manner previously described and validated (Celver et al., 
2010; Octeau et al., 2014).  HEK293 cells seeded in a 96-well plate at a density of 
5x104cells/well were transfected with Halotag D2R cDNA.  48 hr post-transfection cells 
were treated with dopamine (10 μM  from 10mM stock that contained 5mM ascorbic acid 
to avoid dopamine oxidation) or vehicle for 45 min at 37 °C.  Following dopamine 
treatment, cells were fixed in 4% methanol-free paraformaldehyde (v/v in 1X PBS, 
15 min, 4 °C) and then washed 2x in 1X PBS.  Wells were blocked for 1 hr at 4 °C with 
5% w/v nonfat milk dissolved in 1X PBS.  The levels of FLAG-tagged surface receptor 
were then assessed by probing with horse radish peroxidase (HRP)-conjugated mouse 
monoclonal anti-FLAG M2 antibody (1:5,000 dilution in 5% w/v nonfat milk dissolved in 
PBS) for 45 min at 20 °C, and then washed 2x in 1X PBS.  Supersignal West Femto 
chemiluminescent substrate was added to each well, and the HRP-catalyzed luminescent 
signal was detected and quantified using the Glomax luminometer. 
Measurement of G-protein activation with BRET. We monitored dopamine-induced D2R-
mediated G-protein activation via bioluminescence resonance energy transfer (BRET) 
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measuring recruitment of G-protein coupled receptor kinase.  Utilization of BRET in this 
manner has been well validated (Kamal et al., 2009; Masuho et al., 2015).  HEK293T 
cells were seeded in 6cm diameter culture dishes at a density of 1x106 cells/dish, and 
transfected with D2R, Gαi, Venus 155-239 Gβ1, Venus 155 Gγ2, and the masGRK3ct 
NanoLuc cDNA.  24 hr post transfection, media was replaced with fresh completed 
DMEM.  48 hr post-transfection, cells were washed 2x in 1X PBS, harvested by 
trituration, and seeded in opaque white-bottomed 96-well plates.  Cells were then treated 
with specified concentrations of dopamine or vehicle, and luminescence measurements 
were made using the POLARstar OPTIMA multidetection microplate reader.  Raw BRET 
signals were calculated as the emission intensity at 520-545 nm (acceptor) divided by the 
emission intensity at 475-495 (donor).  Net BRET was found by subtracting the average 
raw BRET ratio before the addition of drug from the average raw BRET ratio after the 
addition of drug.  Dopamine response was calculated by subtracted the net BRET in 
dopamine treated cells from that observed in vehicle treated cells.  
 
G-protein coupled receptor ER co-localization measured with BRET. To assess the 
cellular localization of the indicated GPCRs, we employed a previously validated BRET 
based protocol (Lan et al., 2012).  HEK293T cells were seeded in 6cm diameter culture 
dishes at a density of 1x106 cells/dish, and transfected with appropriate amounts of V-
PTP1b, FLAG-D2R-RLuc8, β2AR-RLuc8, or β2AR W158A-RLuc8.  24 hr post 
transfection, media was replaced with fresh completed DMEM.  48 hr post-transfection, 
cells were washed 2x in 1X PBS, harvested by trituration, and seeded in opaque black and 
white 96-well plates.  V-PTP1b fluorescent signal intensity was measured at 520-545 nm 
in the black-bottomed 96 well plate, following excitation at 490 nM using the POLARstar 
OPTIMA multidetection microplate reader.  Coelenterazine h (5 μM) was added to all 
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wells of the white-bottomed plate immediately prior to measurement, and luminescence 
measurements were made with the POLARstar OPTIMA multidetection microplate 
reader.  V-PTP1b emissions measured at 520-545 nM were normalized against the 
measured fluorescence intensity for each transfection group.  BRET ratios were then 
calculated by dividing the normalized 520-545 nM emission intensity by that measured at 
475-495 nM.  
Immunocytochemistry. HEK293T cells were cultured on cover slips, coated with poly-D-
lysine, in a 12-well plate at a density of 1x105 cells/well, and transfected with indicated 
cDNA constructs.  24 hr post transfection, cells were treated with indicated antipsychotics 
or vehicle.  48 hr post-transfection, cells were fixed and permeabilized by incubation with 
ice cold methanol for 10 min on ice or at 4 °C. Cells were washed 3x in 1X PBS, and 
blocked in 5% (w/v in 1X PBS) nonfat milk for 1 hr at 20 °C. FLAG-tagged receptor was 
probed for with Anti-FLAG M2 Antibody (1:1000 dilution in 5% nonfat milk) overnight 
at 4 °C. Cells were then washed 2x with PBS for 15 min at 20 °C, and then probed with 
fluorophore-conjugated anti-mouse secondary antibody (1:1,000 dilution in 5% w/v 
Nonfat milk) for imaging under fluorescent microscopy. Images were taken with a Zeiss 
Confocal Microscope, and Pearson co-localization coefficients (PCCs) with indicated 
cellular markers determined using the Zeiss imaging software.  
Triton X-100 Biochemical Fractionation of D2R.  To asses APD effect on the detergent 
solubility of D2R, we employed a similar method of fractionation to those described in 
our previous publications (Octeau et al., 2014; Sharma et al., 2013b).  Briefly, HEKT293T 
cells expressing D2R were treated with indicated APDs at the specified concentrations, or 
vehicle for 24 hr.  48 hr post-transfection cells were lysed in TX100 lysis buffer consisting 
of 2% Triton X-100 (v/v in 1X PBS) and 1X SigmaFast Protease Inhibtior (made 
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according to manufacturer’s guidelines, Sigma-Aldrich) 1 hr at 4 °C.  To pellet TX100-
insoluble proteins, cells were centrifuged at 10,000 g for 10 min at 4 °C.  Supernatant 
fractions were separated, and the TX100-insoluble pellet was washed 2x in ice cold 1X 
PBS.  Supernatant proteins (TX100-soluble) were precipitated by the addition of 
trichloroacetic acid (final concentration 10% v/v).  Supernatant protein pellets were then 
washed 3x in ice cold 95% v/v acetone at 4 °C.  Both TX100-soluble and –insoluble 
fractions were resuspended in equal volumes of SDS/urea sample buffer (2% w/v SDS, 
0.01% w/v bromophenol blue, 8 M urea, 20 mM dithiothreitol, 50mM Tris-HCl, pH 6.8). 
Samples were heated for 10 min at 65 °C and then sonicated 20x at a power setting of 5 
for approximately 0.5 sec to reduce viscosity. Equal volumes of the samples were resolved 
using sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), and 
relative protein expression was compared via Western blotting. 
Assessment of APD effect on surface D2R expression via Western blot. HEK293T cells 
expressing D2R were treated with the indicated APDs and the specified concentrations or 
vehicle, approximately 24 hr post-transfection. 48 hr post transfection, total cell surface 
receptor was labeled by incubation with Anti-FLAG M2 antibody (1:5000 dilution in 
complete DMEM) for 1 hr at 37 °C. Unbound excess antibody was removed by washing 
2x in 1X PBS, and TX100-soluble and –insoluble fractions were isolated as described 
above. Proteins were resolved sing SDS-PAGE, and relative protein expression was 
compared via Western Blotting. Relative expression of surface D2R was detected by 
probing blots with anti-IgG antibody against the M2 antibody.  
Western Blotting. Proteins resolved by gel electrophoresis were transferred to methanol 
wetted PVDF membranes (Imobilon-FL, EMD Millipore) by Western blotting apparatus 
(IBI Scientific) in 1X Transfer buffer (25 mM Tris base, 192 mM glycine, 20% v/v 
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methanol).  Membranes were blocked by incubation with 5% (w/v in 1X PBS) nonfat milk 
for 1 hr at 20 °C.  FLAG epitope tagged proteins were detected by incubating the 
membranes with HRP-conjugated anti-FLAG M2 antibody (Sigma-Aldrich 1:5000 
dilution in 5% w/v nonfat milk in 1X PBS).  Following primary antibody incubation, 
membranes were washed 2x with 1X PBS for 15 min at 20 °C.  When necessary, blots 
were then probed with HRP-conjugated secondary antibody, and washed again 2x in 
1XPBS for 15 min at 20 °C.  Supersignal West Femto chemiluminescent substrate was 
then added to each blot, and the chemiluminescent signal was detected using a Chemidoc 
XRS Molecular Imager (Bio-Rad Laboratories). When comparing TX100-soluble and –
insoluble fractions of a cell sample, proteins in both fractions were loaded onto a single 
gel, and transferred to a single PVDF membrane. 
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Fig. 1.    Effect of antipsychotic drug (APD) treatments on cellular levels of D2 
dopamine receptor constructs. 
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Fig. 2.  APD modulation specifically of cell-surface D2R removal. 
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Fig. 3.  Specificity of APD-mediated upregulation of cell surface receptors.    
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Fig. 4.    Effect of APD treatments on the cellular localization of D2R. 
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Fig. 5.    Effect of APD treatments on cellular levels of D2 dopamine receptor short 
form construct 
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Fig. 6. Cellular site for the action of APDs in enhancing cell surface D2R expression.  
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Fig. 7.  Effect of APD treatment on the surface expression of misfolding and 
glycosylation D2R mutants.    
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Fig. 8.  APD modulation of D2R detergent solubility.    
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Fig. 9.  Interactions of β2AR, the misfolding β2AR mutant, β2ARW158A with the ER 
markers, Sec61 and PTP1b.    
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Fig. 10.  G protein signaling and APD-mediated enhancement of D2R surface 
expression.    
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FIGURE LEGENDS 
Fig. 1.    Effect of antipsychotic drug (APD) treatments on cellular levels of D2 
dopamine receptor constructs.   
APD treatments were performed on HEK293 cells transiently expressing the indicated 
receptor constructs.   
A. Dose-response curves of APD-induced enhancement of D2R surface expression and 
effect of clozapine (10 µM) co-treatment on haloperidol dose-response curve.  Cells were 
treated for 24 hr with receptor-saturating (10 µM) concentrations of the indicated APDs.  
The levels of cell-surface D2R were then quantified by probing the intact, non-
permeabilized cells with anti-FLAG antibody and are reported as a percent of 
haloperidol’s maximum effect (percentage increase in surface receptor relative to vehicle). 
Treatments are labeled as: haloperidol alone (solid circles), olanzapine (diamonds), 
clozapine alone (solid squares), haloperidol and 10 µM clozapine (open circles) Receptor 
levels after treatment with haloperidol only were significantly greater than all other 
treatments, receptor levels after treatment with olanzapine were significantly greater than 
those obtained after clozapine treatment, and receptor levels after treatment with 
haloperidol only were significantly different from those obtained after clozapine co-
treatment (mean ± SEM, n = 7, Student’s t-test, p < 0.05).   
B. Effect of antipsychotic drug (APD) treatments on surface expression of D2R.  The 
levels of cell-surface D2R transiently expressed in HEK293 cells were quantified, as in 
“A”, after treatment with receptor-saturating (10 µM) concentrations of the indicated 
APDs. †All APDs, except for clozapine and aripiprazole produced significantly enhanced 
surface D2R expression compared to vehicle and ‡D2R surface expression after clozapine 
treatment was significantly less than after treatment with all APDs, except 
aripiprazole (mean ± SEM, n = 31-32, Tukey’s HSD, p < 0.05).   
C. Effect of APD treatments on total cellular expression of D2R, assessed by ELISA.  
Cells were treated, as in “A”, with the indicated APDs (10 µM, 24 hr), and permeabilized 
with the detergent, triton-X100 (TX100).  Total cellular D2R was then assessed by 
probing with anti-FLAG antibody and levels are reported as a percent of the signal from 
vehicle-treated cells. †Aripiprazole displayed significantly less total cellular D2R signal 
that all other tested APD treatments (mean ± SEM, n = 6-16 Tukey’s HSD, p <.05).   
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D. Time course of haloperidol effect on surface expression of D2R.  Levels of cell-surface 
D2 were evaluated after treatment with Haloperidol (10 µM) for 6, 12, and 24 hr, as in 
“A”, and are reported as a percentage of haloperidol’s effect following 24 hr treatment. 
Surface D2R expression levels after each time point were significantly different from each 
other (mean ± SEM, n = 6, Tukey’s HSD, p < 0.05). 
 
Fig. 2.  APD modulation specifically of cell-surface D2R removal.  
A. Effect of antipsychotic drug (APD) treatment on the specific removal of FLAG-
HaloTag D2R from the plasma membrane examined via pulse-chase labeling with biotin.  
HaloTag PEG Biotin reagent was used to specially biotinylate the cell surface pool of an 
N-terminal FLAG-HaloTag D2R construct transiently expressed in HEK293 cells.  After 
washing-off unreacted HaloTag PEG Biotin reagent, cells were treated with the indicated 
APDs (10 µM, 24 hr), and the biotin-tagged HaloTag D2R remaining at the surface after 
APD treatment was quantified by probing the intact, non-permeabilized cells with 
horseradish peroxidase (HRP)-conjugated streptavidin.  †The levels of biotinylated 
receptor that remained at the surface after aripiprazole treatment was significantly lower 
than that observed after vehicle, haloperidol or clozapine treatment (mean ± SEM, n = 8, 
Tukey’s HSD, p < 0.05).   
B. Effect of dopamine treatment on the internalization of the HaloTag D2R construct.  
HEK293 cells transiently expressing the extracellular N-terminal HaloTag D2R construct 
were treated with either vehicle or dopamine (10 µM) for 45 min. The N-terminal 
HaloTag D2R also contains an extracellular FLAG epitope and the levels of the receptor 
construct remaining at the cell surface after dopamine treatment were quantified by 
probing the intact, non-permeabilized cells with anti-FLAG antibody and are reported as a 
percent of the signal from the vehicle-treated cells.  †Surface receptor levels were 
significantly less after dopamine treatment (mean ± SEM, n = 14-16, Student’s t-test, 
p < 0.05).   
C. Effect of antipsychotic drug (APD) treatment on surface expression of the HaloTag 
D2R construct.  HEK293 cells transiently expressing the extracellular N-terminal HaloTag 
D2R construct were treated with the indicated APDs (10 µM, 24 hr) following which the 
surface receptor was specifically biotinylated by treating the intact cells with HaloTag 
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PEG Biotin ligand.  The levels of biotinylated receptor were then quantified by probing 
the intact, cells with HRP-conjugated streptavidin and are reported as a percent of the 
signal from vehicle-treated cells.  †The levels of cell-surface receptor after either 
haloperidol or clozapine treatment was significantly higher than with vehicle and 
significantly different from each other (mean ± SEM, n = 14-16, Tukey’s HSD, p < 0.05).   
 
Fig. 3.  Specificity of APD-mediated upregulation of cell surface receptors.    
A. Effect of antipsychotic drug (APD) treatment on the surface expression of the β2-
adrenergic receptor (β2AR).  HEK293 cells transiently expressing an extracellular N-
terminal FLAG-tagged β2-AR construct were treated with the indicated APDs (10 µM, 
24 hr).  Following APD treatment, the levels of cell-surface β2AR were quantified by 
probing the intact, non-permeabilized cells with anti-FLAG antibody and are reported as a 
percent of the signal from vehicle-treated cells (mean ± SEM, n = 12).    
B. Effect of antipsychotic drug (APD) treatment on the surface expression of the mu-
opioid receptor (MOR).  The levels of cell-surface MOR transiently expressed in HEK293 
cells were evaluated after treatment with the indicated APDs (10 µM, 24 hr) as in “A” and 
are reported as a percent of the signal from vehicle-treated cells (mean ± SEM, n = 12).   
C. Effect of antipsychotic drug (APD) treatment on the surface expression of the non-
binding D2R mutant, D2R D114A.  The levels of cell-surface receptor in HEK293 cells 
transiently transfected expressing an extracellular N-terminal FLAG-tagged D2R D114A 
construct were evaluated after treatment with the indicated APDs (10 µM, 24 hr) as in 
“A”, and are reported as a percent of the signal from vehicle-treated cells (mean ± SEM, 
n = 16).   
D. Effect of antipsychotic drug (APD) treatment on the total cellular expression of the 
non-binding D2R mutant, D2R D114A.  The levels of total receptor in HEK293 cells 
transiently expressing the extracellular N-terminal FLAG-tagged D2R D114A construct 
were evaluated after treatment with the indicated APDs (10 µM, 24 hr) by probing the 
triton-X100 (TX100) permeabilized cells with anti-FLAG antibody and are reported as a 
percent of the signal from vehicle-treated cells (mean ± SEM, n = 16). 
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Fig. 4.    Effect of APD treatments on the cellular localization of D2R.  
 
A. Confocal microscopy images of cellular distribution of D2R after APD treatments.  
HEK293 cells transiently co-expressing the extracellular N-terminal FLAG-tagged D2R 
construct and a Sec61-RFP fusion, a marker for the endoplasmic reticulum (ER) were 
treated with the indicated APDs (10 µM, 24 hr).  Representative images of D2R cellular 
distribution (green, left column), Sec61cellular distribution (red, central column) and the 
level of D2R-Sec61 co-localization (yellow, right column) following treatment with 
vehicle (top row), haloperidol (central row) and clozapine (bottom row) are depicted.  
Each row represents confocal microscope scans of the same field.    
B. Quantification of the extent of colocalization between D2R and Sec61-RFP.  The graph 
depicts the colocalization coefficient, quantified in cells coexpressing D2R and Sec61-
RFP, and defined as the number of pixels positive for both D2R and Sec61, expressed as a 
percent of pixels positive for D2R, after APDs treatment.  †The correlation coefficient of 
D2R colocalized with Sec61 was significantly reduced after haloperidol treatment when 
compared to either vehicle or clozapine treatment (mean ± SEM, n = 25-46 cells, Tukey’s 
HSD, p < 0.05). 
 
Fig. 5.    Effect of APD treatments on cellular levels of D2 dopamine receptor short 
form construct 
A. Effect of APD treatments on surface expression of the D2-dopamine receptor short 
form (D2Rsh) construct.  Cells were treated for 24 hr with receptor-saturating (10 µM) 
concentrations of the indicated APDs.  The levels of cell-surface D2Rsh were then 
quantified by probing the intact, non-permeabilized cells with anti-FLAG antibody and 
are reported as a percent of the signal from vehicle-treated cells.  †The levels of cell-
surface D2Rsh measured after haloperidol treatment was significantly greater than after 
clozapine or vehicle treatment (mean ± SEM, n = 12, Tukey’s HSD, p < 0.05). 
B. Effect of APD treatments on total cellular expression of D2Rsh assessed by ELISA.  
Total cellular levels of D2Rsh were evaluated after treatment with the indicated 
APDs (10 µM) as in “A” and are reported as a percent of the signal from vehicle-treated 
cells (mean ± SEM, n = 16).  
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Fig. 6. Cellular site for the action of APDs in enhancing cell surface D2R expression.  
A. Effect of coexpression of the OCT1 transporter on the dose-response curves for 
amisulpride-mediated enhancement of cell-surface D2R expression.  HEK293 cells 
transiently expressing the extracellular N-terminal FLAG-tagged D2R construct 
alone (circles) or coexpressing the OCT1 transporter (squares) were treated (24 hr) with 
the indicated concentrations of amisulpride.  The amisulpride-mediated 
enhancement (over vehicle) of cell-surface D2R was quantified by probing the intact cells 
with anti-FLAG antibody and is plotted as a percent of the maximum 
response (mean ± SEM, n = 15).  The EC50 that was modeled for amisulpride 
enhancement of cell-surface D2R expression was significantly less in OCT1 cDNA 
cotransfected cells (10 nM and 663 nM, respectively). The 95% confidence interval for 
the EC50 ratio ranged from 0.003 to 0.03.   
B. Effect of coexpression of the OCT1 transporter on the dose-response curves for 
tiapride-mediated enhancement of cell-surface D2R expression.  Dose-response curves for 
tiapride-mediated enhancement of cell-surface D2R expression were generated, plotted 
and modeled as in “A” (mean ± SEM, n = 15-16).   
 
Fig. 7.  Effect of APD treatment on the surface expression of misfolding and 
glycosylation D2R mutants.    
A. Effect of antipsychotic drug (APD) treatment on the surface expression of the 
misfolding D2R mutant, D2RW158A.  HEK293 cells transiently expressing an extracellular 
N-terminal FLAG-tagged D2RW158A mutant construct were treated with the indicated 
APDs (10 µM, 24 hr).  The relative levels of cell-surface receptor were then quantified by 
probing intact cells with anti-FLAG antibody and are reported as a percent of the signal 
from vehicle-treated cells.  †The signal for cell-surface receptor after haloperidol treatment 
was significantly higher than in untransfected cells, or cells treated with either vehicle or 
clozapine (mean ± SEM, n = 7-14, Tukey’s HSD, p < 0.05).   
B. Effect of antipsychotic drug (APD) treatment on the total cellular expression of the 
misfolding D2R mutant, D2RW158A. Representative Western blot depicting the effect of 
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treatment with the indicated APDs (10 µM, 24 hr) on total cellular expression of 
misfolding D2R mutant, D2RW158A. 
C. Quantification of total cellular expression of the misfolding D2R mutant, D2RW158A.  
HEK293 cells transiently expressing the extracellular N-terminal FLAG-tagged D2RW158A 
mutant construct were treated with the indicated APDs (10 µM, 24 hr) as in “A”.  After 
APD treatment, Western blots of the cell lysates subjected to SDS PAGE were probed 
with either anti-FLAG antibody or an anti-actin antibody and total cellular receptor signal 
was normalized to the actin signal and is reported as a percent of the signal from vehicle-
treated cells (right panel) (mean ± SEM, n = 3).   
D. Effect of antipsychotic drug (APD) treatment on the surface expression of the D2R 
glycosylation mutant, D2RN5,N17,N23→Q.  HEK293 cells transiently expressing an 
extracellular N-terminal FLAG-tagged D2RN5,N17,N23→Q mutant construct were treated with 
the indicated APDs (10 µM, 24 hr) and the relative levels of cell-surface receptor were 
quantified as in “A” and are reported as a percent of the signal from vehicle-treated 
cells.  †The signal for cell-surface receptor after haloperidol treatment was significantly 
higher than in untransfected cells, or cells treated with either vehicle or 
clozapine (mean ± SEM, n = 7-14, Tukey’s HSD, p < 0.05).   
E. Effect of antipsychotic drug (APD) treatment on the total cellular expression of the 
D2R glycosylation mutant, D2RN5,N17,N23→Q.  HEK293 cells transiently expressing an 
extracellular N-terminal FLAG-tagged D2RN5,N17,N23→Q mutant construct were treated with 
the indicated APDs (10 µM, 24 hr), as in “C”, and the relative levels of total receptor were 
quantified by probing triton-X100 (TX100) permeabilized cells with anti-FLAG antibody 
and are reported as a percent of the signal from vehicle-treated cells (mean ± SEM, 
n = 16) .  
Fig. 8. APD Modulation of D2R solubility 
A. Effect of APD treatment on the TX100 solubility of D2R.  Representative Western blot 
depicting the effect of treatment with the indicated APDs (10 µM, 24 hr) on the 
segregation of D2R, transiently expressed in HEK293 cells, into TX100-soluble (S) and 
insoluble (I) biochemical fractions.   
B. Quantification of the TX100 solubility of D2R after APD treatment.  Quantification of 
the percent of total cellular D2R, that segregates into the TX100-soluble fraction, as 
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shown in “A”, after treatment with the indicated APDs (10 µM, 24 hr).  †Treatment with 
haloperidol, but not clozapine, increased the TX100-solubility of D2R compared to 
vehicle (mean ± SEM; n = 4-6, Tukey’s HSD, p < 0.05).   
Fig. 9.  Interactions of β2AR, the misfolding β2AR mutant, β2ARW160A with the ER 
markers, Sec61 and PTP1b.    
A. Confocal microscopy images of cellular localization of β2AR and the misfolding β2AR 
mutant, β2ARW160A with respect to the ER marker, Sec61.  Representative images of the 
cellular distribution of the N-terminal FLAG-tagged β2AR (green, top left, wild-type), the 
N-terminal FLAG-tagged misfolding β2AR mutant, β2ARW160A (green, bottom left) and 
the ER marker fusion protein, Sec61-RFP (red, central column) and the level of receptor-
Sec61-RFP co-localization (yellow, right column) in HEK293 cells transiently expressing 
the respective constructs.    
B.  Relative BRET between the ER marker Venus-PTP1b (V-PTP1b,) and β2AR-RLuc8, 
β2ARW160A-RLuc8 or FLAG-D2R-RLuc8.  BRET-mediated excitation of V-PTP1b by the 
indicated receptor-RLuc8 fusions was normalized against expression levels of both V-
PTP1b and the receptor-RLuc8 fusion and then reported as a percent of the normalized 
BRET signal obtained with β2AR-Rluc.  †All of the BRET responses are significantly 
different from each other and ‡BRET between V-PTP1b and the D2R construct was 
significantly less than with either the β2AR or the misfolding β2ARW158A 
construct (mean ± SEM, n = 8 cells, Tukey’s HSD, p < 0.05). 
 
Fig. 10.  G protein signaling and APD-mediated enhancement of D2R surface 
expression.    
A.  Effect of pertussis-toxin (PTX)-co-expression on APD-mediated enhancement of D2R 
surface expression.  HEK293 cells transiently coexpressing the extracellular N-terminal 
FLAG-tagged D2R construct and a fusion of the catalytic subunit of PTX with GFP were 
treated with the indicated APDs (10 µM, 24 hr) and the relative levels of cell-surface 
receptor were quantified and reported as a percent of the signal from vehicle-treated 
cells.  †The signal for cell-surface receptor after treatment with either clozapine or 
haloperidol was significantly different and different from that in vehicle-treated 
cells (mean ± SEM, n = 16, Tukey’s HSD, p < 0.05).   
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B.  Effect of APD treatment on dopamine and D2R-mediated G protein activation.  
HEK293 cells transiently coexpressing constructs for D2R, Gαo, Venus-Gβγ, 
masGRK3ct-NanoLuc were treated with either vehicle, haloperidol or clozapine (10 µM, 
24 hr) after which the cells were washed and then treated with the indicated 
concentrations of dopamine.  The level of dopamine-elicited G protein activation was 
measured by evaluating the increase in BRET that occurs between free Gβγ-Venus and the 
masGRK3ct-NanoLuc construct and are plotted as a function of the maximal response 
obtained with 10 μM dopamine (mean ± SEM, n = 3-6).  The EC50 for dopamine in the 
vehicle-treated cells obtained by nonlinear fit of the data was 24 ± 3.6 nM.  No dopamine 
responses were obtained in the APD-treated cells even after cells were washed for 2 hr.    
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APPENDIX 1: Introduction and Review of the Problem 
Schizophrenia is a seriously debilitating mental disorder affecting ~1% of the world’s 
population. Although antipsychotic drugs have been on the market for the last 70 years, 
they lack efficacy in treating schizophrenia’s most incapacitating symptoms, and produce 
serious and sometime irreversible side-effects. One drug, clozapine, has shown clinical 
efficacy superior to all other available antipsychotics, resulting in what clinicians describe 
as patient awakening. However utility of clozapine is drastically limited as it produces a 
fatal adverse effect in 1% of treated patients. There is currently no molecular/mechanistic 
explanation for clozapine’s uniquely superior efficacy. I have observed a unique 
molecular action of clozapine, which could potentially explain its unique efficacy. This 
study will further investigate the nature of that molecular action, and seek to provide 
evidence of a unique interaction between clozapine and the shared target of all 
antipsychotic drugs. 
 
D2-dopamine receptors (D2R): D2R are seven-pass transmembrane domain G-protein 
coupled receptors (GPCRs)(Beaulieu and Gainetdinov, 2011). They belong to the D2-like, 
or pertussis toxin (PTX) sensitive Gi/o-coupled dopamine receptors, inhibiting the 
activation of the cAMP pathway (Beaulieu and Gainetdinov, 2011; De Mei et al., 2009). 
Most highly concentrated in the striatum, D2R are the most widely expressed D2-like 
receptors, found also in the substantia nigra, cortex, and many other brain areas (Beaulieu 
and Gainetdinov, 2011b; De Mei et al., 2009). D2R is a clinically relevant receptor, as all 
clinically available antipsychotic drugs (APDs) bind D2R at therapeutic concentrations 
(Ginovart and Kapur, 2012; Nord and Farde, 2011). Alternative splicing leads to two 
isoforms of D2R, D2R Long (D2L) and D2R Short (D2S), differing by 29 amino acids in 
the 3rd intracellular loop (Beaulieu and Gainetdinov, 2011b). D2L is primarily expressed 
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post-synaptically while D2S functions mainly as an autoreceptor pre-synaptically 
(Beaulieu and Gainetdinov, 2011). 
 
Schizophrenia and APDs: Schizophrenia is an extremely debilitating mental disease, 
affecting about 1% of the world’s population (Freedman, 2003b). The disease is 
characterized by three categories of symptoms: 1) “Positive”, psychotic symptoms, like 
hearing voices, 2) negative symptoms, like attention deficit or anhedonia, and 3) 
Cognitive dysfunction, often leading to social and vocational impairment (Freedman, 
2003b). The severity of these symptoms is such that 10% of patients diagnosed with 
schizophrenia ultimately commit suicide (Siris, 2001). Introduction of APDs 70 years ago 
proved revolutionary in the treatment of schizophrenia, reducing many of the positive 
symptoms, and allowing for discharge of many institutionalized patients (Freedman, 
2003b; Muench and Hamer, 2010; Nord and Farde, 2011). Clinical potency of the APDs is 
closely correlated with their affinity for D2R (Freedman, 2003b; Howes and Kapur, 2009; 
Muench and Hamer, 2010; Nord and Farde, 2011; Seeman, 2010). But, APD efficacy does 
not share this correlation, and the underlying cellular mechanisms relating D2R blockade 
and APD efficacy are not understood (Howes and Kapur, 2009; Muench and Hamer, 
2010). The only common link between APDs is they target D2R at therapeutic 
concentrations (Freedman, 2003b; Muench and Hamer, 2010; Seeman, 2010). Therefore, 
focus was predominantly laid on D2R blockade, and drugs designed in this manner are 
collectively called the first generation antipsychotics (FGAs) (Howes and Kapur, 2009; 
Muench and Hamer, 2010).  
 
FGAs and Extrapyramidal Symptoms (EPS): Rudimentary hypotheses of APD action 
state that clinical APD efficacy results from D2R blockade in the cortex (Howes and 
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Kapur, 2009; Tandon, 2011b). However, signaling of D2R expressed in the striatum is 
heavily involved in controlling voluntary locomotor activity, and blockade of D2R by 
APDs in the striatum can produce serious locomotive side-effects known as EPS 
(Beaulieu and Gainetdinov, 2011b; Muench and Hamer, 2010; Nord and Farde, 2011; 
Seeman, 2010; Tandon, 2011b). Acutely, FGAs have the potential to produce 
Parkinsonism, but, with chronic treatment, also have the potential to cause an irreversibly 
debilitating dyskinetic disorder, tardive dyskinesia (TD). Due to their lack of efficacy in 
treating the negative and cognitive symptoms, and the common incidence of serious EPS, 
management of schizophrenia with FGAs is critically inadequate (Tandon, 2011b). 
 
Clozapine and Second Generation Antipsychotics (SGAs): In the 1970s clozapine was 
introduced with superior clinical efficacy compared to FGAs (Nord and Farde, 2011; 
Wahlbeck et al., 2000; Wenthur and Lindsley, 2013b). Clozapine displayed efficacy 
against the negative and cognitive symptoms, as well as the positive symptoms, along 
with the ability to treat patients refractory to the FGAs (Tandon, 2011b; Wahlbeck et al., 
2000; Wenthur and Lindsley, 2013b). Furthermore, clozapine displayed a markedly 
reduced propensity of inducing EPS (Muench and Hamer, 2010; Seeman, 2010). 
However, it was discovered that treatment with clozapine causes life-threatening 
agranulocytosis in nearly 1% of treated patients (Alvir et al., 1993; Farooq and Taylor, 
2011; Pirmohamed and Park, 1997). As a result of these findings, use of clozapine has 
been limited to patients unresponsive to other neuroleptics, and only with stringent 
haematological monitoring (Farooq and Taylor, 2011; Pirmohamed and Park, 1997). 
Clozapine’s superior clinical efficacy provided motivation to develop a second 
generation of antipsychotic drugs, with the goal of reproducing clozapine’s efficacy and 
reduced induction of EPS, while also avoiding agranulocytosis (Jibson and Tandon, 1998; 
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Kuroki et al., 2008). Identifying and mimicking unique pharmacological properties of 
clozapine as compared to the FGAs became the focus of antipsychotic development. 
Along with a reduced affinity for D2R, it was found that clozapine displayed higher 
binding affinities for other brain receptors, most notably serotonin receptors. Mimicking 
this “atypicality” of clozapine gave rise to the second generation antipsychotics (SGAs), 
or therapeutic agents designed specifically with a reduced affinity for D2R and higher 
affinity for serotonin receptors (Jibson and Tandon, 1998b; Kuroki et al., 2008b; Nord and 
Farde, 2011).  
In the midst of promised superior clinical efficacy, and despite much higher cost, 
SGA use has become the standard for schizophrenia pharmacotherapy (Freedman, 2003b; 
Meltzer, 2013b). However, despite their decreased tendency to cause EPS, SGAs cause 
many of their own serious side effects including: weight gain, type II diabetes mellitus, 
and dysplipidemia (Meltzer, 2013b). Furthermore, multiple non-commercial, 
independently funded clinical studies such as CUtLASS, CATIE, and EUFEST revealed 
no difference in efficacy between FGAs and SGAs, and notwithstanding their reduction in 
EPS, SGAs were found to be no more tolerable than FGAs (Leucht et al., 2009; Lewis and 
Lieberman, 2008b; Naber and Lambert, 2009; Tandon R et al., 2007) 
Clozapine’s clinical efficacy is superior to both FGAs and SGAs: Clozapine, however, 
evidenced by the above mentioned clinical studies and other private meta-analysis, 
continues to outperform FGAs and SGAs in terms of clinical efficacy, tolerability and 
reduction of schizophrenia related mortality (Agid et al., 2010b; Kerwin and Bolonna, 
2004b; Leucht et al., 2009; Lewis and Lieberman, 2008b; Meltzer, 2013b). Time and 
again, clozapine succeeds in the wake of disappointing outcomes with other APDs; 
consistently effective in treatment-resistant patients (Farooq and Taylor, 2011; Meltzer, 
2013b). While some consider clozapine the “Gold Standard” SGA, others view its 
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unduplicated success as reason to discuss it separately from other “atypical” APDs 
(Meltzer, 2013b). Outcomes of clozapine treatment have even been described as 
“awakenings”, as patients experience “restoration of [their] lost souls to near normal 
existence” (Stahl, 1997).  Evidence even suggests that clozapine may exhibit 
antiparkinsonian effects, further distinguishing its superior motor system side effect 
profile (Casey, 1989b). Unfortunately, agranulocytosis has critically limited the utility of 
this fabulous APD (Farooq and Taylor, 2011; Pirmohamed and Park, 1997). 
 
Pharmacological basis for Clozapine’s activity: Though many explanations have been 
suggested, the molecular mechanisms behind clozapine’s pharmacological superiority 
remain unknown (Wenthur and Lindsley, 2013b).  Initially, it was believed to be 
clozapine’s enhanced ability to target serotonin receptors centrally (Kuroki et al., 2008b). 
As previously discussed, SGAs were designed in this line of thinking, and results from the 
aforementioned clinical studies has greatly diminished support for this theory (Leucht et 
al., 2009; Lewis and Lieberman, 2008b; Naber and Lambert, 2009; Tandon R et al., 2007).  
Investigation of clozapine’s binding of D4DR has also proven unfruitful, as drugs that 
share this property do not replicate clozapine’s efficacy (Kramer et al., 1997).  
As other hypotheses continue to fail, many researchers accept that binding of D2R 
by APDs is central for their clinical efficacy (Kapur and Mamo, 2003b; Vauquelin et al., 
2012). It has been suggested that clozapine’s “atypicality”, while not a function of 
serotonin receptor activity, is due to lower D2R occupancy/quicker dissociation, or “fast-
off” antagonism (Vauquelin et al., 2012). Fast-off binding to D2R by clozapine or other 
SGAs reduces interference of D2R signaling, and in the striatum may explain the reduced 
incidence of EPS seen with many of the atypical APDs (Seeman et al., 1997; Vauquelin et 
al., 2012). The reduced D2R occupancy is likely the result of the lowered affinity for D2R 
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that clozapine and the SGAs share, and this concept is the basis for the “fast-off theory” of 
their “atypicality” (Seeman et al., 1997; Vauquelin et al., 2012). 
Yet neither the serotonin theory nor the fast-off theory explain the unique clinical 
efficacy of clozapine. As previously stated, drugs that share these properties have been 
developed, and pale in comparison with clozapine in multiple independent clinical trials 
(Leucht et al., 2009; Lewis and Lieberman, 2008b; Meltzer, 2013b; Naber and Lambert, 
2009; Tandon R et al., 2007).  Keeping in mind that the common link between all 
available antipsychotics is binding of D2R at therapeutic concentrations, one can deduce 
that the superior clinical efficacy of clozapine results from a unique and currently 
undescribed molecular action of clozapine at D2R not shared by any other available 
antipsychotic drug. This unique property of clozapine is unlikely to be the cause of cardio-
metabolic side effects, as these are shared by the SGAs (Meltzer, 2013b). However, it is 
possible that this property could be the cause of the agranulocytosis, as this adverse effect 
seems to be specific to treatment with clozapine (Farooq and Taylor, 2011; Pirmohamed 
and Park, 1997).  
In preliminary experimentation, I have observed the first evidence of such unique 
actions of clozapine at D2R. 1% of the world’s population suffers from schizophrenia, and 
1 in 10 patients will take their own life (Freedman, 2003b; Siris, 2001). In other words, 1 
in every 1000 people will take their own life as a direct result of schizophrenia. Further 
investigation of our discovery could result in better drugs to treat this severely debilitating 
and unfortunately prevalent disease.  
Recent discoveries have begun to change receptor-ligand theory. It is well established that 
GPCRs can exist in many functional conformations that can each illicit specific signaling 
(Hall et al., 1999). It has also been shown that ligands can stabilize unique conformations 
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of receptors; allowing for one ligand to antagonize one receptor mediated signal, while 
activating/preserving another function of that same receptor (Drake et al., 2008; Luttrell, 
2014; Makita and Iiri, 2013; Violin and Lefkowitz, 2007). Thus, many unique 
confirmations of a receptor are possible in response to different ligands. As previously 
mentioned, it is now being accepted again that binding of D2R plays a central role in 
antipsychotic activity (Kapur and Mamo, 2003b). Here, I am suggesting that clozapine’s 
unique therapeutic effect is neither a function of binding other brain targets nor fast-off 
kinetics, but an ability to stabilize D2R in a conformation distinct from that produced by 
the other APDs. Here, I have described molecular and cellular actions of APDs produced 
via binding to at D2-dopamine receptors that suggest that clozapine-binding induces a 
D2R conformation distinct from that produced by every APD that was tested.  Binding of 
other APDs produce D2R conformational alterations that enhance detergent-solubility and 
enhance insertion into the cell-surface.   
Initial Observation of Unique Clozapine Activity 
As my project design and specific aims were an outcome of my initial observation, I will 
first describe this observation.  
Membrane trafficking of GPCRs is a highly regulated process, involving a variety of 
chaperone proteins, and depending heavily on the biochemical properties of the receptor 
itself (Dong et al., 2007). Our lab studies many properties of D2R, including the nature of 
its expression in the cellular membrane (Sharma et al., 2013b). Along these lines, we 
investigated the ability of APDs to effect D2R membrane expression using a cell-surface 
ELISA in a 96-well plate format. Briefly, Human Embryonic Kidney 293T cells 
(HEK293T) were transiently transfected with plasmid DNA coding for Human D2R. 24 hr 
post transfection, the cells were treated with receptor saturating concentrations of various 
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antipsychotic drugs. Following 24 hr treatment the non-permeable intact cells were probed 
with a horseradish peroxidase (HRP) conjugate antibody targeting a specific epitope fused 
to the N-terminus of D2R. Addition of substrate for HRP, and subsequent reading with a 
Glomax plate reader, revealed relative levels of cell membrane surface D2R expression. I 
observed that this long-term (24 hr) APD treatment, in the absence of dopamine treatment, 
dramatically increases levels of cell-surface D2R with respect to vehicle, while clozapine 
produced the smallest increase (Fig. 1). This method of measuring cell-surface receptor 
has been previously described and validated (Celver et al., 2012b; Octeau et al., 2014), 
and saturation concentrations were used to achieve maximum effect to remove any 
confounders. The dose-response curves depicted in figure 1 prove that concentrations used 
were sufficient to reach maximal response and binding saturation. There was no observed 
correlation between affinity for D2R and propensity to cause increased surface expression. 
For example, haloperidol has a much higher affinity for D2R than clozapine, while 
quetiapine has a much lower affinity. In our assay, both haloperidol and quetiapine caused 
dramatically greater increases in surface D2R than that of clozapine. This suggests that the 
displayed phenomenon is not resulting from the extent of D2R binding achieved by each 
drug, but rather unique binding interactions with the receptor. This observation led to our 
suspicion that clozapine’s unique therapeutic effect results from an ability to stabilize 
D2R in a conformation distinct from that produced by the other APDs, evidenced by its 
reduced tendency to increase D2R cell-surface expression. One other APD, aripiprazole, 
also showed significantly less cell-surface D2R expression than all other APDs, except for 
clozapine. While all other tested APDs were antagonists of D2R, aripiprazole, a relatively 
new APD, is a partial agonist of D2R (Burris et al., 2002). Aripiprazole’s partial agonism 
of D2R may cause agonist induced internalization of D2R or down-regulation through 
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other signaling pathways (Marchese et al., 2008). Further investigation of aripiprazole was 
required to distinguish its action from that of clozapine, and is discussed below. 
Any display of unique actions of clozapine at D2R is exciting in its own right. However, 
for this observation to result in development of better pharmacotherapies for the treatment 
of schizophrenia, we first had to further investigate the nature of this phenomenon. Below 
I have discussed 3 specific research aims I addressed to better describe clozapine’s 
individuality among the other APDs in mediation of cell-surface expression of D2R. The 
experimental strategy to address each aim is listed and described in Appendix 2.  
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APPENDIX 2: Study Design and Specific Methodology 
 
Specific Aim 1: Describe the origins of and further characterize the observed 
increase in cell-surface D2R  
As previously mentioned, membrane trafficking of GPCRs is a heavily regulated process, 
mediated by many chaperone proteins, and dependent upon many biochemical properties 
of the receptor itself (Dong et al., 2007). At any given point in time, cell-surface 
expression levels are a function of both newly synthesized membrane-inserted receptor 
and removal of “older” cell-surface receptor to endocytic vesicles (Dong et al., 2007; 
Marchese et al., 2008). Therefore, APDs could be affecting either side of this balance 
between new receptor insertion and old receptor removal. However, a third explanation is 
also possible. It is logical to predict that simply increasing translation of D2R would 
increase receptor levels in any cellular pool, including both intracellular and cell-surface 
populations. Therefore, the question must be answered, is the phenomenon a function of 
an increase in total D2R expression, increased D2R membrane insertion, or decreased 
cell-surface D2R removal? Secondly, it is important to know if this observation is 
conserved between both D2L and D2S isoforms. Thirdly, it is essential to demonstrate that 
the increased cell-surface expression is specific to D2R, and similar results are not 
observed in other classes of GPCRs.  
There is much overlap of export chaperone proteins across many classes of GPCRs, and it 
is possible that the ADPs may be targeting one of these proteins (Dong et al., 2007). Thus, 
this possibility must be ruled out. Finally, further distinction must be explored between 
aripiprazole mediated D2 surface expression and that of clozapine. It is possible that 
aripiprazole causes unique down regulation of D2R, its partial-agonist activity leads to 
agonist induced internalization of the receptor, or it shares clozapine’s unique 
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functionality. Still, head to head comparison with clozapine must be performed in order to 
investigate this potential commonality.  
APD treatments achieve effect saturation. It was important to display that the drugs used 
in our experiments were reaching saturation binding, or a maximum effect on surface 
expression to remove confounders of varying drug affinities.  Therefore, we generated 
dose-response curves using increasing doses (10-10,000 nM) haloperidol, clozapine, and 
olanzapine, to display that they are reaching their maximum effect at the concentrations 
used in previous experiments.  These results are discussed in the manuscript and 
Appendix 3, and the data is summarized in Fig. 1A. 
 
Is increase in D2R simply a function of increase in total receptor? To answer this 
question, I performed a variation of the previously described ELISA method that allowed 
for access to surface and intracellular D2R pools. HEK293T cells were cultured in a 96 
well plate, and transiently transfected with cDNA coding for human D2R. 24 hr post-
transfection, cells were treated with receptor saturating concentrations of the indicated 
APDs and appropriate vehicle. 48 hr post-transfection, cells were fixed and permeablized 
by incubating with ice cold methanol at -20 °C for 15 min.  This method of 
permeabilization for antibody probing of intracellular antigens/proteins has been well 
validated (Jamur and Oliver, 2010; Krutzik and Nolan, 2003). Wells were blocked for 1 hr 
at 4 °C in 5% w/v nonfat milk dissolved in PBS. Total FLAG-tagged D2R signal was 
assessed by probing with HRP-conjugated anti-FLAG M2 antibody (1:5,000 dilution in 
5% w/v nonfat milk dissolved in PBS)(Sigma). Supersignal West Femto 
chemiluminescent substrate (Pierce-ThermoFisher Scientific) was added to each well, and 
the luminescent signal was measured using a multi-plate luminometer (Glomax). Thus any 
APD mediated increase in total D2R was determined by comparing chemiluminescent 
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signals from APD treated cells with vehicle treated cells. Results of this experiment are 
discussed above in the manuscript, and data is depicted in Figure 1C.  
Is increase due to reduced removal from the surface or increased membrane insertion? I 
investigated this question in two ways. First, to exclusively estimate removal of D2R from 
the cell-surface, I used a variation of a pulse-chase assay utilizing specific covalent 
labeling of surface D2R fused with HaloTag®(Promega). Pulse-chase assays used for 
similar purposes have been previously described (Yamaguchi et al., 2009). HaloTag is a 
dehalogenase enzyme designed to form specific irreversible covalent bonds with linkers in 
specifically designed HaloTag ligands in-vitro (Los et al., 2008b; Urh and Rosenberg, 
2012). This experiment will utilize the HaloTag-PEG-Biotin ligand (Promega, cat#G8591) 
that is membrane impermeable, and therefore only labels surface receptor. A fusion 
HaloTag-D2R cDNA construct was created as described in the manuscript, with the 
HaloTag enzyme fused to the N-terminus of D2R, which is extracellular. This construct 
was used in a similar cell-surface ELISA, however, 24 hr after transfection, and prior to 
APD treatment, surface HaloTag-D2R was specifically labeled by incubation with 
membrane-impermeable HaloTag-PEG-biotin ligand (100 nM in complete DMEM, 1 hr, 
37 °). Unreacted reagent was removed by washing 2X with 1X PBS. In this manner, 
specifically the population of surface D2R was labeled immediately prior to APD 
treatment. Cells were then treated with receptor- saturating concentration of APDs for 
24hr. Remaining PEG-biotin labeled surface receptor was then probed for by incubating 
with HRP-conjugated streptavidin (1:10,000 3% w/v BSA in 1X PBS), which covalently 
binds biotin. Therefore, addition of chemiluminescent substrate will reveal signal only for 
receptor left of the population labeled 24 hr post-transfection. Because newly-synthesized 
receptor will not have this label, the surface receptor signal will be merely a function of 
what has not been removed, and therefore allows for comparison of rates of removal of 
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surface-D2R between different APD treatments as well as the vehicle. If, for example, in 
this experiment the APD treated cells display increased surface-D2R levels compared to 
vehicle, then this indicates a reduced rate of removal of surface D2R with APD treatment. 
If surface D2R signal appears no different from that of vehicle treated cells, this indicates 
that the rates of surface D2R removal are similar, and the explanation for the previously 
observed APD mediated increase of surface D2R is likely an increase in membrane 
insertion of D2R.  Results of this experiment are explained in the manuscript, and the data 
is depicted in figure 2A. Control ELISAs were conducted to display similar behavior 
between the HaloTag-D2R and WT-D2R constructs, such as agonist-induced receptor 
internalization, and APD enhance surface receptor expression. Results of these 
experiments are also discussed in the manuscript, and the data summarized in figure 2B-C. 
Secondly, I conducted a cell-surface ELISA with a D2R mutant, IYIV212-215A. This 
mutation blocks D2R- β-arrestin binding required for agonist-induced internalization of 
D2R in mammalian cells (Lan et al., 2009). Thus cell-surface ELISAs using this mutant 
under conditions of APD treatment will display an APD’s ability to influence membrane 
insertion. The data from these experiments were not included in the manuscript, but is 
summarized in Figure 11 in Appendix 4.  
Is the surface-D2R increase conserved with both D2R and D2Rsh?To address this 
question, the original cell-surface ELISA was repeated with cDNA coding for FLAG-
D2Rsh, in a head to head comparison with D2R, displaying any differences/similarities. 
Total D2Rsh expression following 24 hr APD treatment was also assessed in the same 
manner as D2R 
Is the effect specific to D2R? I answered this question by simply repeating the cell-surface 
ELISA and APD treatment with a non-dopamine receptor GPCR. To this end, APD effect 
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on FLAG-tagged β2-adrenergic receptor (β2-AR) and FLAG-tagged Mu Opioid Receptor 
(MOR) expression was assessed in both surface and total cellular receptor ELISAs. 
 
 Is Clozapine’s activity unique to that of Aripiprazole? Further distinction between 
clozapine and aripiprazole was realized in the previously described HaloTag pulse-chase 
experiment, and is discussed in Appendix 3. Additionally, aripiprazole could cause 
increased D2R removal from the surface due to its partial-agonist activity, through agonist 
induced internalization.   I explored aripiprazole’s ability to cause endocytosis of D2R in 
response to short-term (45 min) treatment. HEK293T were seeded in a 96-well plate at 
5x104 cells/well, and transiently transfected with D2R. 48 hr post-transfection, cells were 
treated with 10 μM aripiprazole, dopamine, or vehicle for 45 min. Cells were then fixed 
with ice cold methanol-free paraformaldehyde (4% v/v in 1XPBS). Wells were blocked in 
5% w/v nonfat milk in 1XPBS for 1 hr at 4 °C, and remaining surface receptor was probed 
for with HRP-conjugated anti-FLAG M2 antibody (1:5,000 in 5% w/v nonfat milk 
dissolved in 1X PBS). Supersignal West Femto chemiluminescent substrate was added to 
each well, and the HRP-catalyzed luminescent signal was detected and quantified by a 
multiplate-luminometer (Glomax). Reduced signal in either of the treated groups 
compared to vehicle indicates agonist-induced internalization of the receptor. Dopamine 
treatment was used as a positive control for receptor internalization. If aripiprazole causes 
receptor internalization, then it is likely that the lower surface signal observed in cells 
treated with aripiprazole for 24 hr is a result of increased removal of receptor from the 
membrane. The results of this experiment were not included in the manuscript, but are 
discussed in Appendix 3, and the data is summarized in Figure 12. 
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Visually Characterizing Cell-Surface D2R Increase: Cellular localization of D2R, along 
with β2-AR and β2-ARW158A (discussed below) was visually characterized using 
Immunocytochemistry (ICC) and confocal microscopy. I conducted the initial 
experiments concerning β2-AR localization, and D2R localization in response to 
clozapine and haloperidol (images not shown). The confocal images and co-localization 
data presented in the manuscript were the result of experiments conducted by my lab-
mate, Craig Irving. We assessed the co-localization characteristics of D2R, β2-AR, and 
β2-ARW158A with mCh-Sec61-beta a known ER marker fused with the red fluorescent 
protein mCherry (Shu et al., 2006; Zurek et al., 2011b). HEK293T cells were cultured on 
cover slips, coated with poly-D-lysine, in a 12-well plate at a density of 1x105 cells/well, 
and transfected with indicated cDNA constructs.  24 hr post transfection, cells were 
treated with indicated antipsychotics or vehicle.  48 hr post-transfection, cells were fixed 
and permeabilized by incubation with ice cold methanol for 10 min on ice or at 4 °C. Cells 
were washed 3x in 1X PBS, and blocked in 5% (w/v in 1X PBS) nonfat milk for 1 hr at 
20 °C. FLAG-tagged receptor was probed for with Anti-FLAG M2 Antibody (1:1000 
dilution in 5% nonfat milk) overnight at 4 °C. Cells were then washed 2x with PBS for 
15 min at 20 °C, and then probed with fluorophore-conjugated anti-mouse secondary 
antibody (1:1,000 dilution in 5% w/v Nonfat milk) for imaging under fluorescent 
microscopy. Images were taken with a Zeiss Confocal Microscope, and Pearson co-
localization coefficients (PCCs) with indicated cellular markers determined using the 
Zeiss imaging software. Pearson coefficients provides a percentage of locational overlap 
between the two fluorescent emissions, but does not normalize for signal intensity.  
 
AIM 2: Display the above APD effect is a result of direct and unique binding 
interactions with D2R Aim 2 will be addressed in 3 ways, using head to head 
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comparisons between the APD displaying the most dramatic increase in surface D2R 
(haloperidol), and clozapine.   
 
Is the above listed APD effect conserved in a ligand-binding deficient D2R mutant? It has 
been reported that mutation of a conserved aspartic acid residue in GPCRs abolishes 
ligand binding (Han et al., 2009b). Creation of an N-terminal FLAG tagged mutant D2R, 
D114A, allowed for investigation APD-mediated enhanced D2R surface expression in the 
absence of ligand binding. I repeated the above described ELISA with D2RD114A to 
explore whether or not the APD enhancement D2R membrane insertion remains. If so, 
this would indicate that the APDs are binding a target other than D2R, perhaps a 
chaperone protein. However, if the effect is lost, then APD enhanced surface expression 
of D2R is a result of direct and specific binding interactions between D2R and APDs. 
Results of this experiment are discussed in the manuscript and the data is summarized in 
figure 3C. Control experiments assessing total cellular D2RD114A in response to APD 
treatment were also completed, and the data is summarized in figure 3D. 
 
Can Haloperidol’s marked increase of surface D2R expression be inhibited by Clozapine 
co-treatment? As stated earlier, Haloperidol causes the largest increase in surface D2R, 
while clozapine causes the least increase. If our hypothesis that clozapine binding 
stabilizes D2R in a unique confirmation is true, then competitive binding between 
haloperidol and clozapine should, to some degree, reduce haloperidol’s effect. I generated 
two dose response curves for haloperidol; one in the presence and one in the absence of 
10 μM clozapine. If clozapine is able to block or shift haloperidol’s dose response curve to 
the right, it would indicate competitive binding between the two drugs. This would be 
further evidence that binding to D2R is required, as that is the common property of these 
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drugs, and that clozapine’s interaction with D2R is unique compared to that of 
haloperidol. Results of this experiment are discussed in the manuscript and in Appendix 3, 
and the data is summarized in figure 1A.  
 
Can APDs rescue misfolded D2R for proper membrane insertion?  
It has been shown that ligands can rescue misfolded protein from aggregation in the ER, 
binding and stabilizing them in a conformation suitable for export (Lan et al., 2012; Lester 
et al., 2012). Furthermore, mutant misfolding GPCRs have been created by mutating a 
conserved tryptophan residue to alanine, and used to display pharmacochaperone abilities 
of ligands (Lan et al., 2012). Utilizing the corresponding D2R mutant, D2RW160A, I 
assessed APD ability to rescue the misfolded receptor for export to the cell membrane. 
D2RW160A surface receptor expression in response to APD treatment was assessed in the 
same manner as above, and total cellular receptor ELISA controls were executed to ensure 
that observed differences were not due to changes in total receptor expression. 
 
Specific Aim 3: Investigate the actions of different APDs on the cell biology and 
biochemistry/biophysics of the intracellular accumulations of D2R.    
 
Is the observed increase in cell-surface D2R a result of drug binding at the cell membrane 
or intracellularly? If direct binding of D2R by the APDs is required for D2R increase at 
the cell surface, then this binding could occur either at the membrane or intracellulary. 
Knowing where the interaction must occur is essential in determining the mechanism for 
increased membrane expression of D2R. If the crucial interaction occurs intracellulary, 
then anything facilitating APD movement across the cell membrane will improve the 
ability of APD-mediated enhancement cell-surface D2R expression. Some APDs, such as 
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amisulpride or sulpride, are poorly membrane permeable, but are substrates for the 
membrane transporter OCT1 (Dos Santos Pereira et al., 2014). Therefore, transient of 
OCT1 will increase intracellular concentrations of amisulpride or sulpride. An enhanced 
potency of amisulpride to increase surface D2R in cells also expressing OCT1, would 
indicate drug movement into the cell is required for the effect, and the key interaction is 
intracellular. Therefore, utilizing the cell-surface ELISA, I generated two dose response 
curves for amisulpride-induced enhancement of surface D2R expression, in the presence 
and absence of OCT1. To further confirm this result, the experiment will be repeated with 
a drug, tiapride, which is not a substrate for OCT1. No observed change in tiapride’s 
potency with OCT1 present would further validate the conclusion that OCT1’s increase in 
amisulpride’s potency was a direct result of its ability to facilitate amisulpride’s 
movement across the cell membrane. The results of the experiments are summarized in 
the manuscript and discussed in Appendix 3, and the data is depicted in figure 6A-B. 
Characterizing D2R localized intracellularly. Following translation, properly folded 
transmembrane proteins, such as GPCRs, are threaded through the membrane of the 
endoplasmic reticulum (ER), as they are trafficked to the cell surface (Alberts et al., 2008; 
Dong et al., 2007). However, many studies have reported D2R displays atypical 
localization in intracellular perinuclear compartments when transiently expressed, in 
multiple cell lines, or endogenously expressed in neurons (Fishburn et al., 1995b; Kim et 
al., 2008b; Kovoor et al., 2005b; Prou et al., 2001b; Sharma et al., 2013b; Tirotta et al., 
2008b). Because most APDs are seemingly altering this cellular localization of D2R, 
while clozapine appears to conserve this distribution, I wanted to further characterize the 
intracellular D2R.  To this end I compared functional co-localization between D2R and 
ER targeted proteins with other GPCRs primarily targeted to the membrane or the ER. I 
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utilized a bioluminescence energy transfer (BRET) assay in which a receptor-Rluciferase 
fusion constructs, excited by a substrate, emits light that, when within 100 Å, will excite 
an acceptor protein, PTP1B-Venus, which will then emit light. This quantifiable light is 
therefore indicative of the extent two proteins, in this case D2R, β2-AR, or β2-ARW158A, 
and PTP1B co-localize. PTP1B is a known ER marker, and therefore can be used to 
evaluate D2R localization in the ER, and the extent to which APDs facilitate D2R export 
from the ER (Monteleone et al., 2012).  β2-AR, and β2-ARW158A have been previously 
with PTP1B-Venus for this purpose (Lan et al., 2012). β2-ARW158A is a misfolding β2-AR 
mutant, with a mutation in the same conserved tryptophan residue as D2RW160A, and 
displays strong ER localization. On the other hand, in previous ICC experiments, I had 
shown β2-AR primarily located at the cell surface. Thus, these two receptors constructs 
were chosen to compare and contrast with the cellular localization of D2R. BRET requires 
a dual emission multidetection microplate reader, such as a POLARstar OPTIMA. The 
experiment was carried out as described in the “Materials and Methods” section of the 
manuscript. Results are summarized in the manuscript and discussed in Appendix 3, and 
the data is depicted in figure 9B. 
  
Is glycosylation of D2R important for APD mediated increase in surface expression? It is 
well established that protein maturation often requires post-translational modifications 
(PTM), and many GPCRs are glycosylated as part of this maturation process on the 
excretory pathway (Dong et al., 2007). It is also known that N-linked glycosylation at the 
N-terminus of D2R is important in regulating proper membrane expression of D2R, (Min 
et al., 2015). Initially, I had proposed to use ICC and image D2R localization in APD 
treated cells in the presence and absence of N-linked glycosylation. The antibiotic 
tunicamycin can be used in-vitro to inhibit N-linked glycosylation, and has been 
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previously described for this use (Girard-Bock et al., 2016). However, tunicamycin 
treatment for such extended periods of time interfered with cell fixation, in this proved 
difficult to image. Alternatively,  I created a glycosylation deficient mutant D2R construct 
(N5,17,23Q) removing all known putative glycosylation sites from D2R (Min et al., 
2015). I then repeated the initial cell-surface ELISA with the D2RN5,17,23Q construct, to 
alternatively show the significance of glycosylation to APD mediated cell-surface 
increase. If, for example, APDs were changing the rate at which D2R was being 
glycosylated, and promoting membrane insertion, then inhibiting all glycosylation of D2R 
should remove APD-mediated enhancement of D2R surface expression. To control for 
APD-mediated changes in total D2RN5,17,23Q, total cellular D2RN5,17,23Q signal following 
24 hr APD treatment was assessed as described above. Results of these experiment are 
summarized and discussed in the manuscript as well as Appendix 3, and the data is 
depicted in figure 7C-D. 
 
What is the role of G-protein Signaling in the above listed APD effect at D2R? It is 
established that a commonality between APDs is there inhibition of D2R mediated 
activation of G-proteins (Masri et al., 2008). I investigated the potential role of G-protein 
signaling on the above listed APD effect at D2R. D2R is coupled to the pertussis-toxin 
(PTX) sensitive Gαi (Beaulieu and Gainetdinov, 2011b). Thus, co-expressing D2R in 
HEK293 cells over-expressing PTX will inhibit any D2R mediated basal level G-protein 
signaling. Therefore I repeated the cell-surface ELISA with HEK293 cells transiently 
transfected with both D2R and PTX, to investigate whether the removal of G-protein 
signaling alters the APD mediated surface D2R increase. The results are discussed in the 
manuscript and data presented in Figure 10A. 
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How is G-protein signaling affected by D2R increase at the surface? To assess the effect 
of APD-mediated enhancement of surface D2R expression on receptor function, I 
monitored dopamine-induced D2R-mediated G-protein activation via bioluminescence 
resonance energy transfer (BRET) measuring recruitment of G-protein coupled receptor 
kinase. The assay exploits G-protein coupled receptor kinase 3 (GRK3) fused with 
luciferase as the BRET donor, and a Gγ fused with Venus as the acceptor. Agonist 
induced G-protein activation results in GRK recruitment for receptor phosphorylation 
(Beaulieu and Gainetdinov, 2011b), bringing the BRET donor and acceptor into adequate 
proximity for energy transfer. Utilization of BRET in this manner has been well validated 
(Kamal et al., 2009; Masuho et al., 2015). For this experiment we again utilized the 
POLARstar OPTIMA multidetection microplate reader. The POLARstar is equipped with 
automatic injectors that allow for automatic addition of agonist to each well. Resulting 
emissions for both wave lengths are then measured over time for each individual well, 
thus removing confounders of timing differences. HEK293T cells were seeded in 6cm 
diameter culture dishes at a density of 1x106 cells/dish, and transfected with D2R, Gαi, 
Venus 155-239 Gβ1, Venus 155 Gγ2, and the masGRK3ct NanoLuc cDNA.  24 hr post 
transfection, media was replaced with fresh completed DMEM.  48 hr post-transfection, 
cells were washed 2x in 1X PBS, harvested by trituration, and seeded in opaque white-
bottomed 96-well plates.  Cells were then treated with specified concentrations of 
dopamine or vehicle, and luminescence measurements were made using the POLARstar 
OPTIMA multidetection microplate reader.  Raw BRET ratios were calculated as the 
emission intensity at 520-545 nm (acceptor) divided by the emission intensity at 475-495 
(donor).  Net BRET was found by subtracting the average raw BRET ratio before the 
addition of drug from the average raw BRET ratio after the addition of drug.  Dopamine 
response was calculated by subtracted the net BRET in dopamine treated cells from that 
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observed in vehicle treated cells. The results of this experiment are summarized and 
discussed in the manuscript, and the data is depicted in figure 10B. 
 
Effect of clozapine treatment on D2R-mediated changes in biochemical profile of Gβ5—
WE have previously reported that co-expression with D2R significantly increases the 
detergent-insolubility of and stabilizes Gβ5 (Octeau et al., 2014). In order to investigate 
potential functional outcomes of clozapine’s unique activity at D2R, we explored the 
effect of clozapine treatment on the biochemical interactions between D2R and Gβ5. 
HEK293T cells co-expressing D2R and Gβ5 were treated with 10 μM clozapine or vehicle 
for 24 hr. Trition X-100-soluble and insoluble protein fractions were isolated as described 
in the “Materials and Methods” section of the manuscript. Relative expression of Gβ5 in 
TX100-soluble and –insoluble fractions was measured as described in the “Western 
Blotting” section of the “Materials and Methods”. Gβ5 protein was probed for as 
previously described, by incubating blots for 1 hr at 4 °C with rabbit polyclonal antibody 
CT215 (anti- Gβ5, 1:5,000 in 3% w/v BSA dissolved in 1X PBS) (Octeau et al., 2014; 
Watson et al., 1994).  
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APPENDIX 3: Theoretical/Speculative Discussion and Implications 
APD’s act as pharmacochaperones of D2R. Several studies have reported on the ability of 
ligands to act as pharmacochaperones for cell surface receptors (Lan et al., 2012; Lester et 
al., 2012; Wüller et al., 2004).  Furthermore, these pharmacochaperones can serve to both 
rescue misfolded receptors, and overcome coded ER retention signals to produce 
enhanced export trafficking of GPCRs (Lan et al., 2012; Lester et al., 2012; Wüller et al., 
2004).  The data presented here clearly show that APD treatment results in increased cell 
surface expression of D2R, with clozapine and aripiprazole displaying the lowest ability to 
do so.  These observed differences in surface receptor expression cannot be attributed to 
enhanced protein expression, as total receptor signal among all APD treated cells, except 
for aripiprazole, was similar, suggesting that APDs cause a redistribution of D2R, 
increasing the percentage of total D2R residing in the cell membrane.  Cells treated with 
aripiprazole displayed significantly lower total receptor expression compared to the other 
APDs, which could explain the observed lower surface D2R expression. If aripiprazole 
treated cells display similar surface D2R expression to those treated with clozapine, but 
dramatically less total receptor expression, then the percentage of total cellular D2R 
residing in the membrane must be much higher in aripiprazole treated cells. Thus, the 
percentage of total cellular D2R residing at the cell surface was higher for all other APDs 
than in clozapine or vehicle treated cells.  Furthermore, the Halotag D2R results show that 
the increased surface D2R signal is not a result of reduced receptor loss from the cell 
surface, but indicates that APDs cause an increase in membrane insertion of D2R.  Again, 
aripiprazole was unique in this experiment, as receptor loss from the surface was 
enhanced in cells treated with aripiprazole. Because aripiprazole treated cells display 
similar surface D2R expression to cells treated with clozapine, but less total receptor 
expression and increased surface receptor loss compared to both vehicle and clozapine 
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treated cells, we can deduce that the rate of membrane insertion of D2R in response to 
aripiprazole treatment compared to clozapine or vehicle treatment is enhanced.  We 
therefore conclude that APD treatment results in a re-distribution of D2R to the cell 
membrane, via increased membrane insertion of D2R, with clozapine uniquely producing 
the smallest effect. This conclusion is confirmed by ICC.  Confocal images and PCCs 
obtained in these experiments clearly display D2R constrained to intracellular pools and 
strong co-localization with ER marker Sec61 in vehicle and clozapine treated cells.  
Conversely, cells treated with haloperidol display greatly enhanced membrane D2R 
staining, and significantly reduced PCCs with Sec61. Thus, in cells treated with vehicle or 
clozapine, D2R is primarily residing in the ER, while in cells treated with haloperidol, 
D2R is primarily targeted to the cellular membrane. 
 
Aripiprazole did not cause internalization of D2R. It is well known that D2R undergoes 
agonist-induced endocytosis, possibly followed by trafficking to lysosomes and receptor 
degradation (Beaulieu and Gainetdinov, 2011b). Because of D2R surface expression in 
cells treated with haloperidol was similar to that of clozapine, we investigated the 
possibility that aripiprazole was causing agonist-induced D2R internalization. HEK293T 
cells were transiently expressing D2R were treated with 10 μM concentrations of 
aripiprazole, dopamine, or vehicle for 30 min, and surface receptor was measured as 
described in Appendix 2. While dopamine produced nearly 50% loss of surface receptor 
relative to vehicle, aripiprazole treatment resulted in no significant change in D2R surface 
receptor (Fig. 12). Therefore, aripiprazole did not acutely cause agonist-induced D2R 
endocytosis.  
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Non-internalizaing D2R Mutant, D2RT225,S228,S229→A , similarly effected by APDs. 
Mechanisms of D2R trafficking, and receptor endocytosis are not fully understood. 
Traditionally, it has been assumed that like other GPCRs, phosphorylation by G-protein 
receptor kinases (GRK) initiates the process of receptor internalization (Beaulieu and 
Gainetdinov, 2011b). However, recent studies have shown D2R desensitization and 
receptor internalization in a GRK-independent manner (Celver et al., 2013; Namkung and 
Sibley, 2004). Moreover, it has been demonstrated that D2R is basally phophosphorylated 
by protein kinase C, and that treatment with PKC activators can induce D2R 
internalization independently of agonist treatment (Namkung and Sibley, 2004b; Thibault 
et al., 2011). Thus, it is plausible, that constitutive internalization of D2R occurs through a 
PCK-dependent mechanism. Furthermore, it has been reported that mutation of PKC 
phosphorylation sites in D2R (T225, S228, S229) inhibit agonist-induced 
internalization (Celver et al., 2013). Therefore, it is likely, though not one hundred percent 
certain, that the D2RT225,S228,S229→A PKC phosphorylation deficient mutant blocks both 
constitutive and agonist-induced internalization. Utilizing the D2RT225,S228,S229→A allows 
for investigation of APD-mediated effects of D2R membrane trafficking under conditions 
of significantly less, if not completely absent, receptor endocytosis. In this case, D2R 
surface expression is primarily a function of newly inserted receptor, rather than a balance 
of receptor membrane insertion and receptor endocytosis. Both haloperidol and clozapine 
treatment produced significant enhanced membrane expression of D2RT225,S228,S229→A 
relative to vehicle, however haloperidol’s effect was significantly higher at 250% relative 
to vehicle (Fig 11). Thus, under conditions where surface receptor is likely primarily a 
function of newly inserted receptor, APDs produced an effect similar to previously 
observed with D2R. These results therefore support the conclusion, that differences in 
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enhanced surface D2R expression among APD treatments results from differences in rates 
of D2R membrane insertion.  
 
Enhanced cell surface D2R expression is an intrinsic effect of APDs requiring specific 
and direct binding to D2R. A possible explanation for this phenomenon is that in addition 
to D2R, APDs bind a separate distinct cellular target important for export trafficking of 
transmembrane proteins. However, an important finding in this study is that increased 
membrane insertion of D2R is a result of direct, specific binding of APDs to D2R.  We 
display with two other GPCRs, β2-AR and MuOR, that APD treatment is unable to 
reproduce this effect with other transmembrane receptors.  Additionally, we utilized a 
ligand-binding deficient D2R mutant, D2RD114A, to clearly show that the effect on surface 
D2R is lost when APD binding to the receptor is abolished.  These data indicate that 
enhanced membrane insertion of D2R is a result of direct APD binding to D2R, and APDs 
can be considered to have efficacy for this response.  This is a significant observation, as 
this is the first time APDs have been shown to have a direct action at D2R other than 
antagonism.  Thus, we reasonably suggest that enhanced membrane insertion of D2R is a 
cellular response induced by APD binding, and APDs be considered agonists for this 
response.  According to this reasoning, review of the dose response curves displayed in 
figure 1 would define haloperidol as a full-agonist of enhanced membrane insertion of 
D2R, while clozapine’s efficacy is significantly reduced compared to both olanzapine and 
haloperidol, should be considered a partial agonist.  Partial agonists, as seen with 
aripiprazole, are often used clinically to effectively inhibit the actions of full agonists 
(Burris et al., 2002; Frankel and Schwartz, 2017).  Hence, dose-response curves generated 
for haloperidol in the presence of clozapine lend further support for this conclusion, as the 
efficacy of proposed full-agonist haloperidol is significantly reduced in the presence of 
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proposed partial agonist clozapine.  This suggests a conserved target for clozapine and 
haloperidol, further adding support to the conclusion that enhanced membrane insertion of 
D2R is an intrinsic effect of APDs, for which haloperidol is a full agonist and clozapine is 
a partial agonist.   
Intracellular binding of D2R by APDs critical for pharmacochaperone effects. Another 
important observation is the increase in potency of amisulpride as a pharmacochaperone 
of D2R with the expression of membrane transporter OCT1.  It has been reported that the 
D2R binding pocket exists within extracellular domains of the transmembrane protein (Shi 
and Javitch, 2004).  With the exception of a few newer partial agonists (Burris et al., 
2002; Frankel and Schwartz, 2017), APDs act as D2R antagonists (Howes and Kapur, 
2009; Muench and Hamer, 2010; Seeman, 2010), and are thus assumed to bind only the 
extracellular domains of D2R at the cell surface. However, the increase in potency of the 
poorly membrane permeable amisulpride in the presence of OCT1 indicates that transport 
into the cell is critical for pharmacochaperone efficacy, and enhanced membrane insertion 
is a result of APD binding to D2R intracellularly.  This is the first evidence of APD 
binding of D2R other than at the cell membrane eliciting a response other than 
antagonism. 
Interestingly, despite their marked ability to increase membrane insertion of D2R, the 
concentration response curves for amisulpiride and tiapride show the response has not yet 
saturated at 10 μM concentrations. As previously mentioned, both amisulpiride and 
tiapride, along with sulpiride, display poor membrane permeability (Dos Santos Pereira et 
al., 2014). While these drugs do display reduced incidence of EPS, it could be simply 
because these drugs do not efficiently cross the blood brain barrier. Here we have shown 
accumulation of APDs inside the cell enhances the APD-mediated increase in membrane 
insertion of D2R. While 24 hr treatment will allow for an equilibrium of diffusion across 
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the cell membrane even for poorly permeable drugs, it is reasonable to assume that less 
amisulpiride, sulpiride, and tiapride accumulates inside of the cell. Yet, at similar doses, 
these APDs are achieving similar maximum effect to many of the other APDs. It is 
possible that these drugs may be most potent in producing this enhancement of D2R 
membrane insertion, as lower amounts of the drug at the site of action produce similar 
effects to the other APDs. Their concentration response curves suggest that higher doses 
will yet achieve higher responses. If there is a link between this pharmacochaperone 
phenomenon of APDs and incidence of EPS, then these results are expected. Just as drugs 
that move poorly across the cell membrane are limited in their ability to enhance surface 
expression of D2R, so would those same drugs that also move poorly across the BBB be 
limited in their propensity to cause EPS.  
APDs can rescue misfolded receptor. Properties of  pharmacochaperones include 
overcoming coded ER retention signals and protein misfolding to promote trafficking of 
transmembrane receptors to the cell surface (Lan et al., 2012; Lester et al., 2012; Wüller et 
al., 2004).  An important feature of the graph depicted in Figure 9B is the observed lack of 
BRET occurring between D2R and ER marker PTP1B despite the fact that D2R shows 
strong co-localization with ER marker Sec61 (Figure 4). This suggests that D2R found in 
the ER may be misfolded, and incapable of participating in BRET. Previous studies have 
utilized mutant, misfolding GPCRs, created by mutating a conserved amino acid residue 
(W160A) to report on pharmacocheprone abilities of ligands (Lan et al., 2012).  Utilizing 
a D2RW160A mutant, we have shown here that haloperidol is able to rescue misfolded D2R 
protein, and promote proper receptor expression in the cell membrane, with expression 
levels approximately 20-fold greater than that of clozapine or vehicle treated cells. 
Clozapine treatment was barely able to raise surface receptor expression above 
background, while vehicle treated cells displayed no significant surface D2R expression. 
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This observation is a strong indication that APDs are behaving as pharmacochaperones for 
D2R, possibly rescuing misfolded receptor, with clozapine displaying a dramatically 
lower ability to do so.  
D2R ER retention and drug effective doses highlight physiological relevance. A common 
criticism of studies such as this is that drug doses used exceed physiologically relevant 
concentrations.  APD concentrations have been measured in the 1-5 μM range in both 
human and rat brains (Baldessarini et al., 1993; Froemming et al., 1989; Kornhuber et al., 
2006).  The dose response curves displayed in figure 1B show significant drug responses 
at drug concentrations in the 100 nM range, well below the in-brain measured 
concentrations.  The physiological relevance of a model where D2R, a transmembrane 
receptor, is primarily targeted to intracellular compartments might also be questioned. A 
critical explanation of our observations is that transiently expressing D2R in HEK293T 
cells has artificially caused the membrane receptor to misfold or aggregate in intracellular 
pools due to over-expression, and these results are simply irrelevant artefacts.  However, 
in numerous previously reported studies, when transiently expressed across multiple cell 
lines, or endogenously expressed in neurons, D2R is atypically localized in intracellular 
perinuclear compartments (Fishburn et al., 1995b; Kim et al., 2008b; Kovoor et al., 2005b; 
Prou et al., 2001b; Sharma et al., 2013b; Tirotta et al., 2008b).  Recently it was reported 
that a di-arginine motifs can function as ER retention signals, and conserved arginine 
clusters in the 3rd cytoplasmic loop of D2R function as such a signal (Kubale et al., 
2016b).  Kubale et al. reported, that while WT D2R localized primarily to the endoplasmic 
reticulum, and disruption of amino acids 267, 268, and 269, all arginines in the 3rd 
cytoplasmic loop of D2R resulted in dramatically enhanced membrane targeting of 
D2R (Kubale et al., 2016b). Hence, this intracellular accumulation of D2R is not 
surprising, and should be expected, as it appears naturally coded to do so.  Interestingly, it 
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has been reported that the two receptor isoforms, D2R and D2Rsh, differ in their cellular 
localization, with D2Rsh displaying much greater membrane targeting (Prou et al., 
2001b).  As previously stated, D2Rsh is a splicing variant of D2R, lacking 29 amino acids 
within the 3rd cytoplasmic loop, including the three arginine residues forming the ER 
retention motif in D2R long isoform.  Since the intracellular localization of D2R has been 
shown to be heavily influenced by the A267-269 ER retention motif, it is not surprising 
that D2sh, which lacks this motif, displays much greater surface expression. It has been 
reported that actions of pharmacochaperones include overcoming ER retention signals to 
promote export of transmembrane receptors to the cell surface (Wüller et al., 2004). If, as 
we propose, that APDs are acting as pharmacochaperones, and, as has been reported, 
D2RL contains a strong ER retention motif that D2Rsh lacks, then APD treatment should 
have a much greater effect on the surface expression of D2R long isoform than D2Rsh.  
This is exactly what we observed. Haloperidol induced increase of surface D2Rsh was 
only half that of D2RL, and while clozapine increased surface expression of D2RL by 
60% over vehicle treated cells, surface D2Rsh expression in clozapine and vehicle treated 
cells were not different.  Therefore, we conclude that our observed intracellular, 
perinuclear expression of D2R is not an artifact, and APDs act as pharmacochaperones of 
D2R evidenced by their ability to rescue misfolded receptor and overcome coded ER 
retention motifs to increase D2R export from the ER to the cell surface.  Moreover this 
highlights the physiological relevance of our finding, as D2R is endogenously coded for 
ER targeting, and APD treatment drastically alters that distribution. 
 
Repeatability with multiple detection methods confirm results are not artifacts. Some may 
criticize these observations as merely a product of poor Anti-FLAG M2 antibody binding.  
Recently, it has been reported that sulfation of N-terminus linked FLAG epitope-tagged 
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D2R greatly reduces binding of Anti-FLAG M2 antiobdy (Hunter et al., 2016), and that 
surface D2R expression was underestimated because  this of FLAG epitope sulfation.  
Thus, some might argue that our observations are simply a function of APDs effecting 
FLAG-epitopte post-translational modifaction, specifically its sulfation, rather than 
pharmacochaperone effects on D2R itself, and the differences we observe are related to 
changes in M2 antibody binding.  We believe this is not the case for two reasons. First, the 
experiments revealing the differences in FLAG D2R recognition because of sulfation were 
done in HEK293 cells stably expressing FLAG D2R (Hunter et al., 2016).  Therefore, 
they were dealing with D2R expression levels dramatically lower than in our model, and 
any differences in receptor recognition observed based on sulfation would be much more 
dramatic than in our system. Secondly, we have repeated the initial observation done with 
Anti-FLAG M2 antibody with multiple detection methods.  The Halotag experiments 
(Figure 2) utilize covalent linkage of PEG-biotin reagent, probed for with HRP-
conjugated streptavidin, which cannot be explained away by FLAG-epitope sulfation.  
ICC experiments, completed in our lab, using D2R fused to yellow fluorescent protein 
display the same punctate, intracellular, and perinuclear distribution of FLAG D2R 
labeled with fluorophore-conjugated Anti-FLAG M2 antibody (data not shown).  Thus, 
we have repeated observations acquired with Anti-FLAG M2 antibody with multiple 
detection methods, suggesting that the pattern of D2R localization we observe is not a 
function of differences in post-translation modification of the FLAG epitope. 
 
First evidence of unique action of clozapine at D2R. Perhaps the most important aspect of 
our data is the unique activity of clozapine at D2R. Since its introduction in the 1970s, 
clozapine has displayed superior clinical efficacy in treatment of the positive, negative, 
and cognitive symptoms of schizophrenia compared with all other available APDs (Agid 
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et al., 2010b; Kerwin and Bolonna, 2004b; Leucht et al., 2009; Lewis and Lieberman, 
2008b; Meltzer, 2013b).  Despite the belief that this superior efficacy came through 
clozapine action at serotonin receptors (Kuroki et al., 2008b), results from multiple 
clinical trial comparing clozapine to drugs designed in this manner have largely disproven 
this theory (Leucht et al., 2009; Lewis and Lieberman, 2008b).  As a result many 
researchers have returned to the belief that D2R remains central to APD efficacy (Kapur 
and Mamo, 2003b; Vauquelin et al., 2012).  Until now, no one has provided any evidence 
for unique actions of clozapine at D2R that could explain its superior efficacy.  The dose 
response curves depicted in figure 1A  clearly show that treatment with haloperidol and 
close structural relative of clozapine, olanzapine both cause dramatically higher increases 
in surface D2R expression than clozapine; an effect we have further characterized as an 
intrinsic pharmacochaperone effect of APDs.  The graph depicted in Figure 1B shows that 
clozapine treatment causes lower surface D2R increases than any of the other tested 
APDs, except for aripiprazole.  As previously discussed, because aripiprazole causes 
increased removal of D2R from the cell surface, and cells treated with aripiprazole display 
lower total D2R expression, it can be deduced that aripiprazole also causes increased 
membrane insertion of D2R with respect to clozapine.  We have displayed in using 
multiple detection methods and D2R mutants that APDs can rescue misfolded D2R, and 
overcome endogenous coded ER retention motifs in D2R to redistribute D2R from 
intracellular perinuclear pools to enhanced cell membrane expression.  However, the 
surface receptor ELISAs, along with PCC values and confocal images obtained via ICC 
show that clozapine treatment does not change the cellular distribution of D2R compared 
with vehicle treated cells. Furthermore, while saturating doses of clozapine can only 
produce 30% of haloperidol’s pharamcochaperone effect, in G-protein activation assays 
24 hr treatment with clozapine can produce equal D2R blockade (data not shown).  This 
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implies a unique binding interaction of clozapine with D2R; able to produce equivalent 
blockade, but far inferior pharmacochaperone abilities at equal levels of binding.  
Consider again the dose response curves depicted in Figure 1A.  Inhibition of haloperidol 
by clozapine co-treatment does not follow the pattern of competitive inhibition (dose 
response curve shift to the right), but of non-competitive. Again this suggests unique 
binding of clozapine to D2R compared with that of haloperidol. However, in experiments 
done with D2RD114A, the ligand-binding deficient D2R mutant, effects on surface and total 
receptor of both haloperidol and clozapine are abolished, implying a like binding pocket 
for both drugs.  In order to reconcile these results, one can conclude, that while clozapine 
and haloperidol share a like binding site, clozapine stabilizes D2R in a unique 
confirmation, that does not promote increased export to the plasma membrane, and, as 
seen in the competition curve in Figure 1A, is able to abolish haloperidol binding.  This 
conclusion is further supported by the solubility data presented in Figure 8B, where 
clozapine treatment is shown to induce unique biochemical properties of D2R relative to 
all other tested APD and vehicle treatments.  Whereas all other drugs increase the 
detergent solubility of D2R, clozapine uniquely reduces its detergent solubility.  
 
Speculative discussion of functional impact of clozapine treatment. Previously our lab 
reported on biochemical interaction of D2R and Gβ5 (Octeau et al., 2014). Co-
pexpression of D2R with Gβ5 produces dramatic increase in Gβ5 detergent insolubility, 
and a marked increase in Gβ5 stability. Gβ5 expression also displayed the ability to inhibit 
agonist-induced internalization of D2R but not MuOR (Octeau et al., 2014). It has been 
reported that accumulation of insoluble protein can be evidence of protein aggregation 
(Basso et al., 2009; Schlager et al., 2012; Shaw et al., 2008). Recall that ER targeted D2R 
was unable to participate in BRET with another ER targeted protein, suggesting that it 
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might be misfolded or aggregated. D2R also displays significant detergent insolubility. 
Therefore, it is possible that D2R has a natural propensity to aggregate, and as seen with 
Gβ5, may cause other proteins to aggregate as well. Protein aggregation has been 
implicated in neurodegenerative diseases such as ALS disease and Huntington’s 
disease (Basso et al., 2009; Furlong et al., 2000; Hatters, 2008). Huntington’s chorea is 
almost indistinguishable from the tardive dyskinesia seen in psychiatric patients (David et 
al., 1987). Hypothetically speaking, D2R could be causing aggregation of other proteins 
that can lead to neurodegeneration similar to that seen in Huntington’s disease, and APD’s 
induce tardive dyskinesia by somehow accelerating this process.  
The tri-arginine ER retention motif suggests that D2R is naturally coded to accumulate in 
the ER. Moreover, clozapine, which displays the smallest incidence of inducing tardive 
dyskinesia, increases the detergent insolubility of D2R. Again, hypothetically speaking, 
perhaps D2R is targeted to accumulate in the ER to prevent it from causing other proteins 
to aggregate, and clozapine, unlike the other APDs, preserves this protective cellular 
distribution of D2R. Along this line of thinking, I investigated the effects of clozapine 
treatment on D2R-mediated changes in the biochemical profile of Gβ5. HEK293T cells 
co-expressing Gβ5 and D2R were treated for 24 hr with 10 μM clozapine or vehicle, and 
the detergent solubility of Gβ5 was assessed as described in Appendix 2. Interestingly, 
treatment with clozapine nearly doubled the detergent solubility of Gβ5 relative to vehicle 
treatment (Fig. 13). Thus, clozapine treatment displays inhibition of D2R-mediated 
changes in the biochemical profile of Gβ5. This observation is striking and intriguing, and 
certainly begs further investigation into the nature of D2R’s interaction with Gβ5. If D2R 
induced protein aggregation does lead to neurodegeneration, and D2R accumulation is a 
purposeful protective mechanism against this outcome, than the ability of clozapine to 
conserve these biochemical properties of D2R could yield neuroprotective effects. 
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Furthermore, since treatment with all other tested APDs mediates D2R export from the 
ER and increases its detergent solubility, then perhaps they are overcoming this 
“protective aggregation” of D2R, and lead to neurodegeneration and tardive dyskinesia.  
Certainly these arguments are purely speculative at this point. However, the preliminary 
result of clozapine’s “protective” actions over the biochemical characteristics of Gβ5 are 
intriguing. Future experimentation should be done to 1) investigate the nature of D2R 
interaction with Gβ5, and other implicated proteins and 2) how APDs alter these 
interactions.  
Implications for drug discovery and pharmacotherapy of schizophrenia— Perhaps this 
evidenced unique binding interaction of clozapine with D2R is the key for its superior 
clinical efficacy.  The concept of ligand bias, where ligands bind the same receptor, but 
produce distinct conformational changes resulting in selective receptor signal activation, 
has been reported on for quite some time (Drake et al., 2008; Erickson et al., 2013; 
Luttrell, 2014; Makita and Iiri, 2013; Violin and Lefkowitz, 2007).  Here we have 
reported that APDs are pharmacochaperone agonists of D2R membrane insertion in 
addition to antagonism of G-protein signaling.  Perhaps, clozapine’s seemingly bias-
ligand binding profile, antagonizing D2R-mediated G-protein signaling while avoiding the 
pharmacochaperone effects of the other APDs, is the key to its superior clinical efficacy.  
If so, these findings harbor great potential for the future of schizophrenia 
pharmacotherapy.   
As previously mentioned, because of the fatal agranulocytosis produced by clozapine, its 
utility and impact in the treatment of schizophrenia is drastically limited (Farooq and 
Taylor, 2011; Pirmohamed and Park, 1997).  However, these results could provide a 
model for APD development, in which investigational compounds can be compared to 
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clozapine to for similar receptor-ligand interactions, while avoiding agranulocytosis.  The 
D2R surface ELISA could theoretically be used as a high-throughput screen for 
investigation APDs; identifying D2R antagonist that do not cause increased surface D2R 
expression. Yet, as seen in the case of aripiprazole, it is also necessary to distinguish 
between APDs displaying lower D2R surface expression because of increased surface 
receptor loss and lower total receptor expression. Additionally, clozapine binding of D2R 
produces unique biochemical effects on the receptor protein. Thus, I propose a novel APD 
development strategy identifying test compounds that display the following 
characteristics: 1) Antagonism of D2R, 2) Insignificant increase of surface D2R 
expression with prolonged treatment, 3) No effect on the rate of surface D2R removal, and 
4) Do not increase D2R detergent-solubility. Unlike FGAs, clozapine does display 
metabolic and cardiovascular side effects. Yet, these side effects are common to of the 
SGAs (Meltzer, 2013b), and are therefore unlikely to be a result of the aforementioned 
unique characteristics of clozapine treatment. However, the side effect of agranulocytosis 
is unique to clozapine, so it is theoretically possible that agranulocytosis could correlate 
with the unique effect profile of clozapine. Currently, the mechanism of clozapine-
induced agranulocytosis is unknown (Alvir et al., 1993; Pirmohamed and Park, 1997; 
Rajagopal, 2005), and developing an in-vitro assay to assess the risk of agranulocytosis is 
not at this point plausible. Nonetheless, these findings are tremendously exciting, as it is 
the first description of a unique effect profile of clozapine at D2R.  Perhaps these results 
are the basis for the development of safe and tolerable antipsychotics that, like clozapine, 
effectively treat all aspects of schizophrenia.  
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APPENDIX 4: Supplemental Figures 
 
Fig.11 (Left). Effect of APD treatment on surface expression of the of the PKC 
phosphorylation mutant, D2RT225,S228,S229→A. 
 
Fig 12 (Right). Effect of aripiprazole treatment on the internalization of D2R 
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Fig. 13. Effect of clozapine treatment on D2R modulation of Gβ5 solubility  
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FIGURE LEGENDS: 
 
Fig.11. Effect of APD treatment on surface expression of the of the PKC 
phosphorylation mutant, D2RT225,S228,S229→A. 
HEK293 cells transiently expressing an extracellular N-terminal FLAG-tagged 
D2RT225,S228,S229→A construct were treated with the indicated APDs (10 µM, 24 hr).  The 
relative levels of cell-surface receptor were then quantified by probing intact cells with an 
anti-FLAG antibody and are reported as a percent of the signal from vehicle-treated cells.  
†The levels of cell-surface receptor after either haloperidol or clozapine treatment was 
significantly higher than with vehicle and significantly different from each 
other (mean ± SEM, n = 24-56, Tukey’s HSD, p < 0.05). 
 
Fig 12 (Right). Effect of aripiprazole treatment on the internalization of D2R. 
HEK293 cells transiently expressing the D2R construct were treated with either vehicle, 
dopamine (10 µM), or aripiprazole (10 µM) for 45 min. D2R contains an extracellular 
FLAG epitope and the levels of the receptor construct remaining at the cell surface after 
dopamine treatment were quantified by probing the intact, non-permeabilized cells with 
anti-FLAG antibody and are reported as a percent of the signal from the vehicle-treated 
cells.  †Surface receptor levels were significantly less after dopamine treatment, but not 
aripiprazole treatment (mean ± SEM, n =16, Student’s t-test, p < 0.05).   
Fig. 13. Effect of clozapine treatment on D2R modulation of Gβ5 solubility 
A. Effect of clozapine treatment on D2R modulation of TX100 solubility of Gβ5.  
Representative Western blot depicting the effect of treatment with the clozapine (10 µM, 
24 hr) on D2R modulation of the segregation of Gβ5, transiently expressed in HEK293 
cells, into TX100-soluble (S) and insoluble (I) biochemical fractions. 
B. Quantification of the TX100 solubility of D2R after APD treatment.  Quantification of 
the percent of total cellular Gβ5, that segregates into the TX100-soluble fraction, as shown 
in “A”, after treatment with clozapine (10 µM, 24 hr).  †Treatment with clozapine, 
increased the TX100-solubility of Gβ5 compared to vehicle (mean ± SEM; n = 4-6, 
Tukey’s HSD, p < 0.05). 
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